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1 Sumário 
Sumário 
A medicina transfusional em cães tornou-se uma prática importante nos últimos 
anos devido às suas demonstradas potencialidades no tratamento de pacientes críticos. 
Os médicos veterinários estão progressivamente a tornar-se familiarizados com os seus 
benefícios e com os riscos associados, mudando as suas práticas no sentido de uma 
utilização mais frequente e consciente de hemocomponentes. Esta evolução tem sido 
suportada por diversos estudos publicados sobre o uso e a eficácia dos produtos 
sanguíneos. Contudo os efeitos fisiológicos de dádivas frequentes e as consequências do 
processamento e armazenamento das unidades recolhidas carecem de investigação. 
Esta tese teve como objetivo investigar a influência da depleção de sangue nas 
variáveis hemodinâmicas dos dadores de sangue, os efeitos de programas de dádivas 
frequentes nos parâmetros relacionados com a biodisponibilidade do ferro e nas 
variações do hemograma, os efeitos da recolha e do processamento das unidades de 
sangue na qualidade dos concentrados de eritrócitos, a influência do armazenamento 
destas unidades na percentagem de hemólise, os riscos das transfusões de sangue, cuja 
compatibilidade é desconhecida (através da identificação da prevalência do antigénio 
eritrocitário canino DEA 1.1), e os potenciais riscos e benefícios das transfusões de 
concentrado de eritrócitos. 
Um total de 57 cães dadores de sangue foi avaliado durante 1 a 2 anos e 327 
unidades de sangue inteiro foram recolhidas e processadas, permitindo o estudo da 
qualidade das unidades de concentrado de eritrócitos obtidas. Finalmente, os registos 
clínicos de 34 cães transfundidos com concentrado de eritrócitos foram revistos de forma 
a avaliar a sua eficácia. 
Os cães não-sedados que doaram 13% ou 15% do volume total de sangue (VTS) 
não evidenciaram variações potencialmente deletérias nas frequências do pulso nem nas 
pressões arteriais. No entanto, após a recolha de 15% do VTS em dadores sedados, 
foram registados potenciais efeitos nocivos, devido a aumentos significativos da 
frequência do pulso. 
As dádivas de sangue trimestrais de 13% e 15% do VTS durante 2 anos foram 
consideradas seguras em cães, já que esta frequência permitiu uma resposta 
regenerativa da medula óssea capaz de restaurar a depleção de células sanguíneas em 
10 dias após as dádivas, mantendo os parâmetros relacionados com a biodisponibilidade 
do ferro dentro do intervalo de referência calculado. A colheita de 13% do VTS cada 2 
meses, durante 1 ano, induziu uma diminuição significativa das reservas de ferro. 
Após o processamento as caraterísticas das unidades de concentrado de 
eritrócitos não foram significativamente diferentes quando relacionados com os efeitos da 
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sedação, da recolha de sangue, do tempo até ao processamento ou dos protocolos de 
centrifugação. Contudo, nas unidades de menor volume, com hematócrito mais elevado, 
com maior tempo até ao processamento e maior velocidade e tempo de centrifugação, 
tenderam a apresentar maior hemólise. Foram detetados valores de hematócrito 
significativamente mais elevados em unidades centrifugadas num programa mais rápido 
e longo (3500 G, 15 minutos). 
A hemólise de unidades de concentrado de eritrócitos aumentou durante o 
armazenamento, especialmente da quinta para a sexta semana. De acordo com as 
normas de medicina humana, (é permitido um máximo de 1% de hemólise numa unidade 
a ser transfundida), os resultados apontam para a necessidade de avaliação da 
percentagem de hemólise em todas as unidades caninas de concentrado de eritrócitos 
com 36-42 dias de vida antes da sua administração, uma vez que quase 51% dessas 
unidades ultrapassou esse limite. Nenhum outro fator relacionado com o processo de 
colheita ou com as caraterísticas da unidade se relacionou com a hemólise. Da mesma 
forma, a hemólise detetada antes do armazenamento demonstrou não ter valor preditivo 
na hemólise registada após o período de armazenamento. 
Os resultados obtidos sugerem que a elevada frequência do antigénio DEA 1.1 
em cães portugueses (56,9%) é responsável por um elevado risco de sensibilização após 
uma primeira transfusão de sangue incompatível, e por uma probabilidade relevante de 
ocorrência de reação hemolítica aguda após uma segunda transfusão incompatível. 
Os benefícios da transfusão de concentrado de eritrócitos foram evidenciados 
pelo aumento médio do packed cell volume (PCV) dos pacientes 3 horas após a 
transfusão. Além disso, todas as variáveis clínicas melhoraram dentro do mesmo período, 
embora só a pulsação, a cor das mucosas e a atividade mental foram significativamente 
diferentes dos resultados pré-transfusionais. Foram registadas apenas 3 reações 
transfusionais febris não hemolíticas, correspondendo a 6% do total das transfusões. A 
taxa de sobrevivência dos pacientes transfundidos foi de 71%, não estando relacionada 
com o volume ou idade das unidades de concentrado de eritrócitos, com a duração da 
transfusão, nem com o tempo de internamento ou o PCV dos pacientes. 
Os resultados deste estudo permitiram esclarecer aspetos importantes sobre a 
segurança da colheita de sangue em dadores de caninos, a qualidade das unidades de 
concentrado de eritrócitos e a eficácia das transfusões deste componente, de modo a 
contribuir para o desenvolvimento de protocolos adequados na medicina transfusional 
veterinária. 
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Abstract 
Transfusion medicine in dogs has become an important practice in the latest 
years, due to its life-saving demonstrated capacities. Veterinary practitioners are 
progressively becoming aware of its benefits, as well as its associated risks, and their 
routines are progressively changing towards a common and conscientious use of blood 
components. Such evolution has been based on several published studies about the use 
and efficacy of blood products, although the physiological effects of repeated donations 
and the consequences of laboratory processing and storage on the final product have 
been scarcely investigated.  
This thesis aimed to investigate and clarify the influence of blood depletion in the 
hemodynamic variables of the donors, the effect of repeated blood donations in their iron 
status and hematologic parameters, the effects of collection and processing on the quality 
of packed red blood cells (pRBC) units, the influence of storage in pRBC hemolysis, the 
risks of untyped blood transfusions by identifying the prevalence of the dog erythrocyte 
antigen (DEA) 1.1, and the clinical benefits and potential risks of pRBC transfusions. 
A total of 57 blood donors were evaluated during 1 to 2 years. In total, 327 whole 
blood units were processed and the obtained pRBC units were studied. Finally, clinical 
records from 34 dogs transfused with pRBC were reviewed to assess transfusion efficacy. 
Non-sedated dogs donating 13% or 15% of total blood volume (TBV) did not 
evidence immediate harmful variations in pulse rates or arterial blood pressures. 
However, in sedated donors, potential deleterious hemodynamic effects were registered 
upon collection of 15% of TBV, with significant increases of pulse rates. 
Quarterly blood donations of 13% and 15% of TBV during 2 years were considered 
safe for canine donors, as these regimens induced a bone marrow regenerative response, 
able to restore depleted blood cells within 10 days while maintaining iron status within the 
calculated reference range. Collection of 13% of TBV every 2 months during 1 year 
induced a significant decrease of iron stores. 
The characteristics of pRBC units after processing were not significantly different 
when factors related to sedation, blood collection, time to processing or centrifugation 
protocols were studied, although units with lower volume, higher hematocrit, longer time to 
processing and higher centrifugation speed and time tended to present higher haemolysis. 
Significantly higher hematocrit values were detected in units centrifuged in a faster and 
longer program (3500 G, 15 minutes).  
Hemolysis of pRBC units increased during storage, particularly from the fifth to the 
sixth week. According to human guidelines (a maximum of 1% hemolysis for the unit to be 
transfused) our results point to the need for hemolysis evaluation of all canine pRBC units 
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with 36-42 days of shelf-life before use, as almost 51% of such units surpassed this limit. 
No other collection procedure or unit characteristics were related to hemolysis. Likewise, 
pre-storage hemolysis failed to predict its value at the end of the storage period. 
 Our results suggest that the frequency of DEA 1.1 expression in Portuguese dogs 
is high (56.9%), hence increasing the risk of sensitization following the first transfusion 
with non-typed/non-crossmatched blood, with a relevant probability of acute hemolytic 
reactions after a second transfusion.  
 The benefits of pRBC transfusion were evidenced by the overall mean increase in 
the patients’ PCV 3 hours after transfusion. Furthermore, all clinical variables improved 
within the same period, although only pulse rate, mucous membrane color and mentation 
were significantly different from the pre-transfusion results. Only 3 non-hemolytic febrile 
transfusion reactions were verified, corresponding to 6% of the total transfusions. The 
survival rate of transfused patients was 71%, with no significant differences being related 
to pRBC volumes and shelf life, duration of transfusion, length of hospitalization, or 
patients’ PCV. 
 The results of these studies allowed to clarify important aspects regarding the 
safety of blood collection for canine donors, the quality of pRBC units and the 
effectiveness of pRBC transfusions, so contributing to the development of adequate 
protocols in veterinary transfusion medicine. 
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6 Chapter I – State of the art 
1 – Introduction 
Transfusion medicine is a multidisciplinary science concerned with the proper use 
of blood products in the treatment of a variety of diseases. It is an increasingly common 
therapy in small animal emergency and critical care medicine, as evidenced by the 
development of dedicated animal blood banks and in-house blood donor programs, as 
well as the increased use of blood components rather than WB, allowing for pathology-
specific treatments. New technological advances improve the benefits of blood 
transfusions, while risks are progressively minimized. In addition, veterinary care has 
been taken into high consideration in response to the increasing demands for better 
treatment options made by pet owners and by higher social concerns about animal 
welfare and animal rights to proper veterinary clinical care. 
Since the nineteenth century, transfusion therapy has been developed in 
veterinary medicine, including the progressive change from universal WB administration to 
the individually tailored use of blood components.1,2 However, transfusion needs in most 
clinics are still met by the administration of fresh WB on an individual basis and by the use 
of employee-owned donors, most likely neither blood typed nor screened for infectious 
blood diseases. Moreover, veterinary community is still facing a lack of scientific formation 
programs in this area, what limits the clinical application of the most recent advances in 
transfusion medicine.  
As this is a very recent clinical area in veterinary medicine, few clinical studies 
have been described in dogs and most of them belong to three major investigation groups 
from the United States of America (USA). Furthermore, several veterinary protocols, 
techniques, good practices and even physiologic mechanisms are extrapolated from 
human studies.  
Blood transfusions should never be used as a definitive treatment for underlying 
diseases. On the contrary, they are a life-saving procedure with transient effects, aiming 
to provide circulatory support and correct deficiencies of some blood components while 
diagnosis is established and etiological treatment becomes effective. Despite the life-
saving properties of blood transfusions, their absolute safety is never guaranteed due not 
only to immune or non-immune mediated transfusion reactions but also to blood borne 
infectious organisms potentially transmitted by transfusion. In an effort to reduce the 
incidence of disease transmission, all blood donors must be appropriately screened for 
infectious diseases. Likewise, rapid and reliable commercial tests were recently 
developed for in-house blood typing and crossmatching, ensuring blood compatibility and 
enhancing blood transfusion safety. The appropriate use of collection, processing, storage 
and administration techniques also limits transfusion adverse events by reducing the risk 
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7 Chapter I – State of the art 
of blood contamination and ensuring red blood cells (RBCs) viability and function, which 
prevents hemolysis. 
Donor welfare has always been a major concern in transfusion medicine, but very 
few studies were performed to achieve secure blood collection protocols that ensure blood 
donor safety, including the blood volume collected per donation and the cumulative effects 
of longer donation periods.  
 
 
2 – Blood donation 
 2.1 – Donor requirements 
Before the admission of a dog to a blood donor program, it must be submitted to a 
careful evaluation, including an anamnesis that should review donor habits, living 
conditions, previous travelling, vaccination program, ectoparasite and endoparasite 
prophylaxis, clinical history and medical treatments. A complete physical exam should 
evaluate the donor ability to be safely submitted to blood withdrawal, and should inspect 
potential signs of infectious diseases able to be transmitted by blood transfusions. 
According to previous reports, there is a consensus regarding the ideal donor 
characteristics, described in Table 1. 
 
Table 1. Blood donor requirements.  
Consensual general characteristics3-13 
 Clinically well with no potential for bacteremia (periodontal disease, wounds, 
abscesses or systemic illnesses) 
 No previous blood-borne diseases 
 Good temperament and easily restrained 
 Routinely vaccinated for distemper, hepatitis, leptospirosis, parainfluenza, 
parvovirus and rabies 
 Appropriate ecto- and endoparasite prophylaxis  
Non-consensual general characteristics 
Weight (kg) > 22.54,8,13, 253,6,10, 305,7,9,11,12 
Age (years) Between 1-78,12, 1-84,6, 2-87; < 810,11; > 113  
Pre-donation hematocrit (Hct) > 40%5,7,9,10,12 
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Table 1. cont’d. 
Other reported characteristics 
No travels to foreign countries3,6 
Easily accessible venipuncture sites11 
No previous blood components transfusion11 
No evidence of cardiac murmur13  
No evidence of repeated seizures13   
Be on a heartworm preventative therapy11,12 
Be on a quality commercial diet11,12 
 
Some authors advocate that female donors have to be nulliparous due to the risk 
of alloantibodies formation against RBCs (sensitization) by contacting with incompatible 
blood from puppies during pregnancy.6,11,12 However a recent study failed to document a 
significant difference between the frequencies of sensitized bitches with and without 
previous pregnancies, which suggest the absence of transplacental immunization in dogs, 
confirming previous reports by Young et al.14,15  Regarding breed selection, it is important 
to consider that Akitas present high physiological levels of intracellular potassium, which 
can induce hyperkalemia in the receptors, particularly by hemolyzed units or in cases of 
hemolytic transfusion reactions.7 Greyhounds are considered the best canine donors due 
to their athletic condition, calm temperament and lower frequency of RBC antigens able to 
induce hemolytic reactions.11  
 
2.2 – Pretransfusion screening tests 
An American College of Veterinary Internal Medicine (ACVIM) consensus 
statement, issued in 2005, provided veterinarians with guidelines for canine blood donor 
screening for infectious diseases.16 According to the expert panel, recommended 
diseases to be tested should meet at least 3 of the following criteria: (1) the disease agent 
is documented to cause clinical infection in receptors via blood transmission (Table 2); (2) 
the disease agent is capable of causing subclinical infection and asymptomatic carriers 
could erroneously be used as blood donors; (3) the disease agent can be cultured from 
the blood of an infected animal; (4) the resultant disease in the recipient is severe or 
difficult to clear. The infectious agents that were recommended to be tested included: 
Babesia spp., Leishmania spp., Ehrlichia spp., Anaplasma spp., Neorickettsia spp. and 
Brucella canis.16  
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Table 2. Infectious agents with proved ability to be transmitted by blood transfusion.  
Infectious agents Reported characteristics of the transfusion-related infection 
Ehrlichia canis17 Transmission from infected donors may occur during the acute 
and chronic stages of the disease.  
Babesia canis18 The donor, although clinically healthy, presented a serum 
antibody titer for Babesia canis > 1:5000. The patient exhibited 
hypotension, weakness and non-hemolytic pyrexia within hours 
after transfusion, and a low number of circulating Babesia canis 
was detected.  
Babesia gibsoni19 A febrile hemolytic process was reported after transfusion with 
contaminated blood.  
Leishmania 
infantum20,21 
Three of seven dogs that received blood from infected donors 
developed serological titers and one of them developed severe 
disease more than two years after receiving pRBC transfusion. 
Both positive titers and clinical signs of visceral leishmaniasis 
were also reported in hamsters after administration of canine 
blood infected with Leishmania infantum. 
Brucella canis22 After transfusion with contaminated blood, bacteria can persist for 
up to 2 years in infected dogs.  
 
Diseases that are conditionally recommended to be tested and should be 
considered in a screening panel include: (1) diseases with documented experimental 
transmission but clinical transmission via transfusion is not described or (2) diseases that 
do not represent a threat to most receptors or are easily cleared by them. This group 
includes the following agents: Trypanosoma cruzi, which should be tested in dogs with 
history of travel to and from endemic areas, Bartonella vinsonii, because its potential 
transmission by blood products is unclear, and Mycoplasma haemocanis, which do not 
induce clinically evident disease in the majority of dogs.16 
The consensus panel also stated that some diseases are restricted to certain 
geographic regions or have higher prevalence in certain breeds, and this should be taken 
into account in the screening panel of canine donors.16 Unfortunately these published 
guidelines do not address the frequency of testing. In human medicine, every individual 
WB unit is screened for infectious diseases, but such protocol is cost prohibitive in 
veterinary medicine.23 In canine programs, the frequency of testing should be adjusted to 
the individual donor situation.11,24 Ideally, practitioners should perform screening tests at 
presentation and repeat them after 3 months, the incubation period of the involved 
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agents.24 In closed canine colonies and resident clinic donors the test should be done 
every 3-6 months, but for volunteer client-owned donors annual testing can be performed, 
provided that it is combined with careful anamnesis, proper physical examination and 
laboratorial tests including complete blood count, biochemical profile, urinalysis and fecal 
exam.4,8,11,12,16,24,25   
One study in the United Kingdom reviewed the infectious agents screening results 
of 262 dogs enrolled in a blood donor program.3 These dogs were randomly selected and 
corresponded to 1-10% of the total program blood donors. The screening panel included 
PCR for the presence of hemotropic mycoplasmas, Bartonella, Babesia, Ehrlichia, 
Leishmania and Anaplasma spp.3 Two hundred and fifty eight (98.5%) dogs were PCR 
negative for all agents, and 4 dogs (1.5%) had positive or inconclusive PCR results (two 
tested for hemotropic mycoplasma and two for Leishmania).3 These dogs were retested 2-
6 months later and negative PCR results were obtained, suggesting that they were either 
false positives or infected at the first sampling time but cleared the infection before the 
second PCR test.3 The possibility of false negative results on the second analysis was not 
postulated. According to authors, these results demonstrated that the prevalence of these 
infectious agents is low, hence the use of blood products is unlikely to represent a high 
risk for the  transmission of infectious agents.3   
Despite the many evidences of the transmission of infectious agents by blood 
transfusions and the publication of the ACVIM Consensus Statement,16 the guidelines are 
often not followed by clinicians and the donor selection is frequently based on physical 
examination of client or clinic-owned dogs, evidencing an absence of signs of infectious 
disease.  One study reported that 36% of veterinary clinics did not evaluate the presence 
of infectious diseases among their donors, 24% searched only for circulating microfilaria, 
and 40% performed one or more tests generally recommended in screening panels.26 
Moreover, crossmatching was performed in 40% of the clinics, donors blood type was 
determined in 32%, whereas receptors were not routinely typed by any evaluated 
practice.26 Economical reasons, unawareness of the potential risks and the absence of 
time required for laboratory processing in an emergency case may justify these clinical 
options that put receptors at a higher risk. 
 
2.3 – Blood collection  
Collection systems, anticoagulants and additive solutions (ASs) 
Products available for canine blood collection are obtained from human practice as 
volumes collected are very similar. The anticoagulants and ASs available for humans 
seem to efficiently ensure viability of canine RBCs during storage as well, according to 
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published studies that evaluated shelf-life and maximal expiration dates. Shelf-life is 
defined as the number of days after collection, assuming proper closed system collection 
and storage, at which 75% RBC viability is maintained in the recipient 24-hour after 
transfusion.27 
Post-transfusion viability (PTV) studies are performed by infusion of radiolabeled 
or biotinylated RBCs followed by measurement of radionuclide activity and percentage of 
labeled cells, respectively, in blood samples drawn at frequent intervals after 
transfusion.28-30 After the maximum storage period, cell lesions may compromise the 
RBCs viability, which will not only significantly decrease their ability to carry oxygen, but 
also potentially trigger transfusion reactions, mainly associated with higher free-
hemoglobin (Hb) concentrations and electrolyte imbalances.31,32  
The collection systems, anticoagulant-preservative solutions and ASs that are 
more frequently used for canine blood collection are described in Table 3. The design of 
commercial collection devices ensure a closed system (with no air contact) from the 
collection to the administration, minimizing the risk for bacterial contamination.8,13 Special 
used plastic bags are not easily broken, facilitate components separation, avoid internal 
contamination, allow for gas exchange and hamper platelet and coagulation factors 
activation.32  
The volume of blood to be drawn should be proportional to the amount of 
anticoagulant in the collection bag.13 Commercial collection bags have 63 mL of 
anticoagulant allowing for the collection of 405-495 mL of blood.8,9,33 Citrate-based 
anticoagulants are the most used and may include the following components:8,33 
 Citrate – prevents clotting and retards glycolysis;  
 Dextrose and adenine – ensure cell viability and function during storage (allow 
for continuation of the glycolytic pathway to help synthesis of adenosine 
triphosphate – ATP);  
 Phosphate – contributes to the adenosine phosphate pool and is a buffer for 
end products of RBC metabolism, such as lactate; 
 Citric acid – prevents glucose caramelization during autoclaving and provides 
optimal pH for RBCs.  
 
Optimal ASs provide cells with adequate nutrients, allowing for better RBCs 
storage conditions. After separation of the plasma, the solution is added to RBCs 
extending their lifespan and facilitating the administration by reducing their viscosity.8,34,35 
Thus, dilution with saline prior to transfusion is not required.34 This process should be 
performed within 72 hours after blood collection.35 Additive solutions may contain factors 
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such as dextrose, adenine, mannitol and sodium chloride, ensuring RBCs to maintain their 
function and viability during storage, preventing their lysis.9,36 
 
Table 3. Commercial available blood collection systems, anticoagulant-preservative solutions and 
ASs more frequently used in canine blood collections. 
Blood collection systems 
Single One bag with anticoagulant-preservative solution. 
For WB storage only, with no components separation. Usually 
used for immediate administration. 
Double One bag with anticoagulant-preservative solution, connected by 
a plastic tube to a second empty transfer bag. 
Allows preparing pRBC without additive and fresh frozen plasma 
(FFP), after centrifugation. 
Triple One bag with anticoagulant-preservative solution, one empty 
transfer bag and one bag with AS, all connected by a plastic 
tube. 
Used for the preparation of additive pRBC and FFP. 
Quadruple One bag with anticoagulant-preservative solution, two empty 
transfer bags and one bag with AS, all connected by a plastic 
tube. 
Used for the preparation of additive pRBC, FFP and platelet 
concentrate or cryoprecipitate. 
Anticoagulant-preservative solutions 
CPDA-1 Citrate, phosphate, dextrose, adenine and citric acid. 
Shelf - life: WB – 20 days37; 28 days10; 35 days35,38 
ACD Citrate, dextrose and citric acid. 
Shelf - life: WB – 21 days35,39; WB – 28 days40  
CPD Citrate, phosphate, dextrose and citric acid. 
Shelf - life: WB – 28 days41,42; 21 days35 
CP2D Citrate, phosphate and double dextrose. 
Shelf - life: WB – 21 days35 
Additive solution 
Adsol® (AS-1) 
Fenwal Laboratories 
Adenine, dextrose, mannitol and sodium chloride.  
Shelf - life: pRBC – 37 days28; 33 days43; 42 days11,35 
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Table 3. cont’d. 
Nutricel® (AS-3) 
Medsep Corporation 
Adenine, dextrose, sodium chloride, citrate, phosphate and citric 
acid.  
Shelf - life: pRBC – 35 days30; 42 days11,35 
Optisol® (AS-5) or 
SAG-MAN 
Terumo Medical 
Adenine, dextrose, mannitol and sodium chloride.  
Similar composition to Adsol® but with lower concentrations of 
glucose, adenine and mannitol. 
Shelf - life: pRBC –  35 days44,45; 42 days11,35,46  
 
Blood collection protocol 
The collection technique is a pivotal step to optimize the final quality of blood 
products, but it is also crucial to ensure donor welfare. The process can be performed 
either by gravity or suction. A recent study compared both methods and concluded that 
suction-based blood collection is faster and safer for the donor, preserving blood 
components when a vacuum chamber is used with reasonable negative pressure (-101.6 
mmHg).47 In fact, there was no difference in the final Hct or hemolysis index between the 
two methods. Although a post-donation decrease of the donors’ systolic blood pressure 
(SBP) was demonstrated, it remained within physiological values in all dogs with no 
significant differences between both methods.47 
Although the suction method proved to be faster, reducing the collection time by 
almost 30%, it was also noisier, a fact that, by hampering the relaxation of some donors, 
may lead to more frequent movements.47 Though the authors considered this method as 
cost-effective, it certainly involves more expenses than the gravity method. Moreover, the 
suction device makes it impractical to use when blood collections are performed in 
different places.  
The full technique for canine whole-blood collection should include:8,33,45 
1. a pre-donation physical exam, including weight measurement; 
2. to place the donor on the examination table in a comfortable either lateral or 
sternal recumbence;  
3. to clip and surgically prepare the puncture site; 
4. to place the collection bag on a gram scale; 
5. to clamp the collection line at 15-20 cm distal to the needle, using a plastic 
hemostat; 
6. to clearly identify the position of the vein, remove the needle cap and insert the 
needle into the jugular vein; 
7. to release the clamp, allowing blood to flow into the collection bag; 
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8. to perform careful agitation of the blood bag every 50-75 mL; 
9. once the desired volume is collected, to clamp the line near the needle, remove 
the needle and apply digital pressure with a gauze over the phlebotomy site for 
5 minutes; 
10. to “strip” the blood left in the tube using a tube stripper, allowing it to mix with 
the anticoagulant in the blood bag, and return it into the tube; 
11. to wrap the puncture site for a minimum of 30 minutes, avoiding bruising or 
hematoma formation; 
12. to heat seal the collection line; 
13. to label the collection bag with: donor identification, blood group, date, used 
anticoagulant and volume collected.  
 
Total blood volume collection and donation frequency 
Although the health and welfare of blood donors should be a major concern, it is 
often neglected or not mentioned in scientific studies. Therefore, there is currently no 
consensus on the ideal frequency of donations, the volume of blood that can safely be 
collected, or the need for nutritional supplementation of blood donors. In human 
transfusion medicine, the Council of Europe recommends up to four blood donations per 
year in men and up to three in women, with a maximum volume of 13% of TBV.23 Human 
recommendations are very different from those published in canine donors (Table 4). 
 
Table 4. Blood volume and frequency of blood donations, according to different authors. 
Volume Frequency  Reference 
22 mL/kg  Every 7-10 days 33,48  
18 mL/kg Every 3 weeks, for 2 years 38 
15 mL/kg  5 
16 mL/kg Every 3 weeks 49 
Up to 20 mL/kg Every 4-6 weeks 
(with iron supplementation) 
50 
9 mL/kg, without fluid replacement 
or   
10-18 mL/kg with fluid replacement  
Every 3 weeks in emergency 
cases, but every 2-3 months is a 
reasonable option 
10 
15-20 mL/kg Every 3 weeks 9 
Up to 20 mL/kg Every 6-8 weeks 4 
15 mL/kg Every 6 weeks 12 
15-20 mL/kg  25 
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2.4 – Donor reactions to blood collection  
Few published reports described post-donation reactions in dogs. According to 
Gibson et al. (2012), adverse effects are uncommon but may include hypotension, 
bruising or bleeding from the venepuncture site and dermatitis, which can be detected 
within a few days after donation.44 Couto et al. (2005) also stated that, according to their 
experience, weakness or syncopal episodes after donation were exceedingly rare in dogs, 
reporting only one event in a Greyhound within 700 collections over ten years.51 A report 
describing a canine donor program evaluated 143 donations from 84 dogs and found 
acute donor reactions (e.g. pallor and light-headedness) in 2.8% of the donations, 
rebleeding in 2.1%, hematoma formation in 4.2% and skin irritation in 0.7%.4 The 
incidence of rebleedings and hematomas was reduced by bandaging the phlebotomy site 
and teaching owners to avoid putting the leash on the collar immediately after donation.4 
Another study found no adverse effects (collapse, weakness or lethargy) on 19 
Greyhound donors after collection of 17-22% of TBV, despite significant but transient 
decreases in SBP.51 Similar results were published in one study of thirteen dogs aiming to 
compare the two blood collection methods, gravity versus suction.47 
 
 
3 – Processing and storage of blood components 
3.1 – Blood components therapy 
Similar to human blood banks, in large veterinary hospitals and dedicated 
veterinary blood banks, blood is processed and separated into different components 
allowing to extend the RBCs  shelf life, while maintaining the functionality of platelets, 
clotting factors, globulin and albumin.12,52 Fresh WB is still the most common product used 
in veterinary practice, because it is readily available to clinicians.25 It is indicated in cases 
of blood losses surpassing 50% of TBV or when multiple components are needed (RBCs, 
platelets, clotting factors and/or albumin).25 However, component therapy offers many 
advantages over WB administration: 1) the separation of a unit of WB (shelf-life of 5 
weeks53) into components extends their expiring date to 6 weeks for pRBC and 5 years for 
frozen plasma;54 2) components may be used to treat more than one dog, maximizing 
treatments per donation; 3) dogs may be given more specific treatment, according to the 
needed components; 4) it reduces the risk of volume overload, as it avoids administration 
of unrequired components, especially in dogs with cardiovascular or renal compromises; 
5) it reduces the risk of transfusion reactions by minimizing exposure to antigens of 
unnecessary components.5,12,38,54-58 The increased availability of blood products, which 
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has resulted from the emergence of several new commercial blood banks, along with a 
better understanding of the components clinical advantages, is changing clinicians’ habits 
towards specific component hemotherapy.58,59 
 
3.2 – Processing methods 
After blood collection, WB units must be immediately refrigerated in order to 
reduce the unit temperature to below 6°C.35,49 However, if platelets activity is to be 
preserved in WB, platelet-rich plasma or platelet concentrate units, those must be 
maintained at 22°C until administration.49,60-62 Plasma processing and freezing at -18°C 
ought to be performed within 8-hours after blood collection, in order to preserve the 
maximum activity of clot factors.35,49 However, a recent study reported that when WB units 
were processed within 24 hours after blood collection, the frozen plasma coagulation 
factor activities (II, V, VII, VIII, IX and X) and hemostatic protein contents (von Willebrand 
factor - vWF, antithrombin and fibrinogen) were maintained, making this a suitable method 
for the production of fresh frozen plasma.63 Whole blood processing allows for the 
preparation of three main components: pRBC, FFP and platelets concentrate. 
Additionally, cryoprecipitate (containing factor VIII, vWF and fibrinogen) and cryopoor 
plasma (with the FFP remaining components) can be prepared from a unit of FFP.49  
Components separation techniques include:11,35,44,49 
1. gentle stir of the WB unit was performed before processing; 
2. proper packaging of the WB unit and remaining system bags into the centrifuge 
cups, avoiding plastic folds or empty spaces, and ensuring a symmetrical 
distribution of the weight between opposite cups; 
3.  centrifugation at 6°C (for RBC and protein preservation) or at 22°C (for 
additional platelet use). Described centrifugation protocols for canine WB 
processing include velocities ranging from 2000-5010 G, during 5-25 minutes, 
mainly with slow deceleration times, as sudden changes in centrifugation speed 
are associated with higher haemolysis;7,8,11,30,33,35,43,49,54,55,64-67 
4. removal of the unit from the centrifuge without agitation and insertion in a 
plasma extractor in order to express the supernatant plasma into a transfer 
empty bag; 
5. addition of the proper volume of AS to the primary pRBC bag, based on a 
proportion of 100 mL AS to 450 mL WB; 
6. aseptical separation of a pRBC aliquot for quality analysis, using a sterile 
connection to a sample bag performed by an electronic connector device; 
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7. after separation of the components, tube sealing, with a thermal sealer, 10 cm 
away from the bag; additional seals along the tube filled with plasma or RBCs 
may be performed to sequester samples for future compatibility tests; 
8. identification of each bag with donor identification, blood type, component, 
volume, date of collection, expiration date and storage temperature; 
9. refrigeration of packed RBCs units as soon as possible at 1-6°C, and of FFP 
units at -80°C, followed by storage at -18°C. 
 
Protocols for the production of canine platelet-rich plasma, platelet concentrate, 
cryoprecipitate and cryopoor plasma have been described by several authors despite the 
relatively low number of studies reporting their use.11,35,44,49,60-62 
 
3.3 – Packed RBCs units 
 As previously described, units of pRBC are obtained after separation of plasma 
content from WB. In addition to erythrocytes, pRBC units contain a small portion 
(approximately 10%) of the original plasma volume.11,68 If leukoreduction is not performed 
and platelets are not separated, non-functional leukocytes and platelets will also exist on 
pRBC units.11 Since triple collection systems with ASs are used, addition of 0.9% saline to 
RBCs reconstitution prior to transfusion is no longer necessary as some authors 
advocate.36,44 Instead, 100 mL of AS are added to erythrocytes, extending their shelf-life 
and reducing the unit viscosity, as previously described.8,34,35 Packed RBCs units with AS 
have a final packed cell volume (PCV) ranging between 55-65% and a volume of 200-300 
mL.9,34,36,68,69 
 
3.4 – Storage lesions 
Storage lesions are physical and chemical changes that occur in RBCs during 
storage, changing their structure and decreasing their function and overall viability after 
transfusion.70 The maximum storage time, or shelf-life, is determined by in vivo evaluation 
of transfused RBCs.35,71 RBCs have normally full viability immediately after collection, but 
ongoing cell damage and degradation during processing and storage progressively 
reduce their viability.72 According to human standards, defined by both the Council of 
Europe and Food and Drug Administration, a minimum of 75% RBCs must have a 24-hour 
in vivo survival after transfusion, and all studies of post-transfusion RBCs viability attend 
to this threshold.71,72 This survival time takes into consideration that nonviable RBCs are 
removed from circulation by the reticuloendothelial system within 24 hours after 
transfusion.72 
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2,3-Diphosphoglycerate (2,3-DPG) 
Additive solutions have a pH of 5.7 that will decrease the pH of pRBC, avoiding the 
caramelization of glucose in heat-sterilized solutions.72 However, in such acid solutions 
2,3-DPG is rapidly depleted from RBCs during storage.36,72 When 2,3-DPG combines with 
deoxyhemoglobin, it enhances the release of oxygen to the tissues, thus its decrease will 
shift the oxyhemoglobin dissociation curve to the left, hence reducing oxygen delivery.36,72-
75 In one study of canine pRBC units, preservation in ADSOL (AS-1) caused a significant 
decrease in 2,3-DPG during 44 days of storage (from 15.2 μmol/g Hb to 3.7 μmol/g Hb).28 
Similar results were obtained with the use of other ASs.76 Fortunately, 2,3-DPG is 
regenerated in vivo after transfusion, reaching 50% of normal values within 7 hours, while 
its complete restoration takes 2-3 days.77 
 
Red blood cells membrane  
During storage the RBC membrane loses flexibility, compromising its normal 
function and hampering microcirculation.36,72,73 The cell morphology changes 
progressively, from biconcave disks to speculated or sphere-shaped cells (echinocytes or 
spherocytes, respectively), decreasing surface-to-lumen ratio.71,75,78 After transfusion, 
these RBCs will either be removed or they will assume the original biconcave shape within 
24 hours.11 Additionally,  RBCs develop microvesicles containing Hb that are released to 
the plasma, causing ongoing spontaneous hemolysis (degradation of RBCs), a 
phenomenon that contributes more to plasma Hb concentration rather than to free Hb 
during storage.78  
 
ATP 
ATP is progressively consumed during storage, especially if cell metabolic activity 
is not reduced by keeping units at low temperatures, usually 4°C.73 The reduction of RBCs 
ATP concentration may lead to protein denaturation and changes in the phospholipids 
composition of their membrane, decreasing its integrity and ability to deform.36,73,74 As 
RBCs rigidity stimulates their removal by the reticuloendothelial system after transfusion, 
ATP levels are directly related to the RBCs shelf-life.75 However, it seems that in dogs the 
RBCs ATP content may not be as vital as in humans.79 
 
Accumulation of proinflammatory substances  
During storage, by-products, mainly released by leucocytes and platelets, will 
accumulate in the pRBC unit. These components include proinflammatory cytokines (IL-
1β, IL-6, IL-8 and tumor necrosis factor-α), histamine, complement and lipids, and are 
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responsible for the degradation of RBCs and transfusion reactions, e.g. febrile 
nonhemolytic transfusion reactions.71,80,81  
 
pH 
The pH of pRBC units decreases during storage.28,75,76 In spite of the left shift of 
the oxygen dissociation curve induced by acidemia, the administration of stored pRBC 
units has no consequences for the transfused patients because the alkaline by-products 
of citrate metabolization tend to reestablish the acid-base equilibrium.75 
 
Other  
Increased osmotic fragility, Hb oxidation and Hb denaturation have also been 
described as RBCs storage lesions that adversely affect their shelf life and function.71,82,83 
Stored erythrocytes also evidenced increased aggregation, secondary to the loss of the 
negative charge in their surface, and increased adherence to endothelial cells, both 
phenomena contributing to a decreased microvascular flow.71 
 
Fresh versus stored pRBC 
Some canine studies evaluated the tissue oxygenation after the administration of 
stored pRBC, when compared to fresh pRBC, reporting either no differences or higher 
oxygenation levels with the use of fresh units, depending on the study.84,85 Although some 
human studies associated the administration of aged pRBC with higher incidence of 
infections, acute renal failure, longer hospitalizations and higher mortality,86-88 two large 
studies of critical anemic patients failed to reveal that morbidity or mortality were related to 
the age of transfused RBCs.89,90 However, some authors advocate that pRBC units with 
more than 28 days should be avoided in the following cases: 
 Critical patients that require massive transfusions. As microvascular flow is 
reduced with the administration of old RBCs, hampering tissue oxygenation, 
patient survival may be at risk because this effect may superimpose a seriously 
compromised oxygen delivery capacity in severely anemic patients. 
Furthermore, these critical patients are often presented in hemorrhagic shock, 
and the consequent peripheral vasoconstriction may aggravate the tissue 
oxygenation deficit.72,91,92 Besides, as stored units have low levels of 2,3-DPG 
that require time to restore after transfusion, severely ill patients may be at 
higher immediate risk if treated with older pRBC.75,93 
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 Patients with hepatic failure. As ammonia levels increase during storage, 
transfusion of stored units may induce or aggravate hyperammonemia and 
encephalopathy in those patients.94 
 
There are no clinical reports documenting an increased morbidity or mortality 
associated with the transfusion of stored rather than fresh canine RBCs.73 
 
 
4 – Blood compatibility 
 4.1 – Definition and genetics 
Red blood cell membranes have species-specific antigens (glycolipids and 
glycoproteins) that constitute the basis for blood groups classification.95,96 These antigens 
may interact with autoantibodies (to self RBCs) or alloantibodies (to other dogs RBCs), 
causing an inflammatory reaction.96 A blood group is defined by the expression of two or 
more alleles in a given locus, responsible for the expression of a particular antigen on the 
RBCs surface.97 These genetic markers vary in immunogenicity and clinical significance, 
determined by three basic factors: 1) the prevalence of each antigen in the population; 2) 
the frequency and titer of natural or induced antibodies by previous transfusions; 3) the 
antibodies affinity to RBCs antigens and consequent induction of agglutination or 
complement activation.12,95,96,98 
There are seven major blood groups in dogs identified with the acronym DEA (dog 
erythrocyte antigen) followed by the numbers 1, 3, 4, 5, 6, 7 and 8.95,99 In addition, 11 
other antigens have been described, with no demonstrated clinical relevance.95 These 
antigens can be co-expressed by the same RBC and vary in frequency with breed, 
geographic location and antisera used.95,100 All groups seem to be transmitted by an 
autossomic dominant genetic mechanism.99 A single dog may or may not present each 
one of the antigens, thus being classified as positive or negative.99 However, the blood 
group DEA 1 presents three alleles sharing the same locus, therefore expressing one of 
three distinct antigens (or none of them): DEA 1.1, DEA 1.2 and DEA 1.3 (the latter 
recently described in Australia, where it seems to be common in German 
Shepherds101).102 The dominant order is DEA 1.1 > 1.2 > 1.3 > 1 negative.99,102,103 Thus, 
each animal can only be positive for one of the antigens or negative for all of 
them.95,99,100,103,104  
Controversial information regarding DEA 1 subtypes has recently come out. In a 
non-published report from Animal Blood Resources International, Kaufman P. (2012) 
stated that DEA 1.1, 1.2 and 1.3 were just different expressions of the same RBC antigen, 
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and that 1.2 antibodies could be considered “weak” 1.1 antibodies, produced after 
exposure to a less antigenic DEA 1.105 Thus, these subgroups should be interpreted like 
subjective determinations of different antigenicity degrees of the same antigen, not 
separate blood types.105 The author also stated that additional studies are needed to 
describe the clinical importance of hemolytic transfusion reactions induced by weak DEA 
1 antibodies (previously reported as 1.2 antibodies) but, while this information is not 
available, dogs typed as 1.2 positive should not be considered DEA 1.1 negative 
donors.105 Similar to this report, two previous studies suggested that 1.2 and 1.3 antigens 
may represent a weaker density of DEA 1.1 on the surface of canine RBCs.103,104   
 
4.2 – DEA system 
Table 5 describes the main characteristics of each antigen, recognized as international 
standards. 
 
Table 5. DEA system antigens description. 
DEA 1 (1.1; 1.2; 1.3) 
Previous nomenclature: A102 
Genetic: This group is a three factor (alleles Aa1, Aa2 and Aa3), four phenotypes system 
– 1.1, 1.2, 1.3 and null type, by order of inheritance.95,104 
Incidence: In USA - DEA 1.1 42-45%;95,106 DEA 1.2 12-20%;95,106 DEA 1.3 identified only 
in Australia.104 
Natural antibodies: No.95,102 
Transfusion reactions: Delayed hemolysis in a first incompatible transfusion and acute 
hemolytic reactions in subsequent incompatible transfusions.95 It is the most clinically 
important blood group, and, as anti-DEA 1.1 antibodies are strong agglutinins and 
hemolysins, this antigen seems to be the major responsible for acute hemolytic 
reactions after an incompatible transfusion to a previous sensitized dog.95,100,107 
Transfused 1.1 and 1.2 positive RBCs to sensitized DEA 1.1 and 1.2 negative dogs will 
be removed in less than 12 hours and 24 hours, respectively.95,100,102,108 No clinical 
transfusion reactions have ever been related to a 1.2 mismatch.109 No reports were 
published regarding the DEA 1.3 antigen incompatibilities.95,104    
DEA 3 
Previous nomenclature: B102 
Genetic: A one factor, two phenotype system – DEA 3 positive or DEA 3 negative, with 
dominance of the first one.102 
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Table 5. cont’d. 
Incidence: In USA – 6-7% DEA 3 positive;106,110 higher frequency in Greyhounds, with 
23% DEA 3 positive.95 Over 60% positivity in native Japanese breeds.111 
Natural antibodies: Yes. Up to 1.2-30% of DEA 3 negative dogs revealed the presence 
of anti-DEA 3 antibodies.95,112,113 
Transfusion reactions: Delayed hemolytic reactions can occur in sensitized dogs, with 
removal of transfused RBCs within 5 days.95 Even though there are no published clinical 
studies to support it, some authors consider that severe acute reactions may also 
occur.95,111,114 
DEA 4 
Previous nomenclature: C102 
Genetic: A one factor, two phenotype system – DEA 4 positive or DEA 4 negative, with 
dominance of the first one.102 
Incidence: In USA – 98% DEA 4 positive.100,106,114 Lower frequency (25%) reported in 
Dobermans.95 
Natural antibodies: No.102 
Transfusion reactions: Contradictory reports.  Sensitized DEA 4 negative dogs did not 
develop hemolytic reactions after transfusion with DEA 4 positive cells.114 One hemolytic 
reaction was described in a DEA 4 negative patient after multiple transfusions of DEA 4 
positive blood.115  
DEA 5 
Previous nomenclature: D102 
Genetic: A one factor, two phenotype system – DEA 5 positive or DEA 5 negative, with 
dominance of the first one.102 
Incidence: Variable according to location.102 In USA, 11-23% DEA 5 positive,95,106 
higher frequency in Greyhounds (up to 30%).95 
Natural antibodies: Yes, in 0.8-10% of dogs from USA.112-114 
Transfusion reactions: Delayed hemolytic reactions can occur in sensitized dogs, 
inducing premature extravascular hemolysis within 3 days.114 
DEA 6 
Previous nomenclature: F102 
Genetic: A one factor, two phenotype system – DEA 6 positive or DEA 6 negative, with 
dominance of the first one.102 
Incidence: Almost 100% in USA.110 Marked breed and geographic variation.116-118  
Natural antibodies: No.102 
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Table 5. cont’d. 
Transfusion reactions: Only one report of a moderately rapid extravascular hemolysis 
in a previously sensitized DEA 6 negative patient, after transfusion with DEA 6 positive 
blood.110 
DEA 7 
Previous nomenclature: Tr102 
Genetic: A two factor, three phenotype system - Tr, O and null, respectively by order of 
dominance.102 Tr is not an integral erythrocyte membrane antigen, but secreted into 
plasma and adsorbed into the RBC surface after being produced in an unknown 
place.119 
Incidence: Tr is present in 9.8-54% of dogs.106,113,118,120-122 
Natural antibodies: Yes. In 20-50% of dogs a low titer (less than 1:8) of antigens was 
reported.95 No alloantibodies were found in another study.100 
Transfusion reactions: Delayed hemolytic reactions can occur in sensitized dogs, with 
sequestration and loss of RBCs within 72 hours.95,110 However, no in vivo or in vitro 
hemolytic reaction was ever reported.99,100  
DEA 8 
Previous nomenclature: He102 
Genetic: Unknown. 
Incidence: 40-50% in USA.123 
Natural antibodies: Unknown. 
Transfusion reactions: Unknown. 
 
 
4.3 – Antibodies and hemolytic reactions 
In dogs, antibodies against RBCs antigens are acquired after sensitization by prior 
incompatible blood transfusion but not by previous pregnancy of offspring with different 
blood groups. In contrast to humans and horses, no transplacental immunization of the 
bitches seems to occur.14,15 Exceptions are the natural antibodies against antigens 3, 5 
and 7, whose presence has been described in some dogs.9,14,95,100,112-114 Although not 
responsible for serious acute hemolysis, these natural antibodies may cause delayed and 
less exuberant reactions, a hypothesis that should be considered even in cases of a first 
transfusion, according to Giger et al. (1995).100 However, delayed transfusion reactions 
associated with those antigens were only reported in previous sensitized dogs, suggesting 
that only induced alloantibodies, and not natural antibodies, are able to produce a 
hemolytic transfusion reaction.14,95,114  
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Blood groups that have proved to cause hemolytic reactions are DEA 1.1,100 DEA 
4115 and, more recently, the presence of Dal antigen124. A hemolytic reaction following 
three different transfusions to the same dog was also reported, but an unknown 
alloantibody, other than DEA 1.1, 1.2, 3, 4, 5 and 7 should be related, according to the 
authors.125 Other non-consensual studies reported, without clinical case descriptions, both 
acute and delayed hemolytic reactions in incompatible transfusions for DEA 1.2,95 DEA 
3,95,111,114 DEA 5,114 DEA 6110 and DEA 795. However, no acute hemolytic reaction was 
reported in a first incompatible transfusion, as no natural antibodies against the most 
antigenic RBCs markers are presented in dogs.7 Indeed, alloantibodies will only be 
produced 3 to 14 days after the first incompatible blood transfusion, inducing a delayed 
reaction that leads to premature and rapid destruction of transfused RBCs, decreasing the 
effectiveness of transfusion.95,98,100 It was estimated that 25% of random primary 
transfusions produce antibodies anti-DEA 1.1 and 1.2.75 In subsequent blood transfusions 
with incompatible blood, the sensitized receiver may immediately develop a serious acute 
hemolytic reaction.7,95,100 Despite the lack of case reports, DEA 1.1 antigen seems to be 
the most important in canine transfusion practice, due to its high antigenicity, high 
frequency in canine population and ability to induce antibodies that react as hemolysins, 
while all others react as hemagglutinins.96,100,125,126  
 
4.4 – New blood groups 
A recent study suggested that the presence of a specific  antigen, Dal antigen, in 
transfused RBCs, may induce transfusion hemolytic reactions in receptors missing this 
antigen and who developed acquired alloantibodies after previous transfusions.124 
Attending to the high frequency of this antigen in the canine population (81% in 
Dalmatians and 93-100% in non-Dalmatians),59,124 the likelihood of a transfusion reaction 
is low and may be similar to that for DEA 4.109 However, any Dalmatian expected to be 
repeatedly transfused should be typed for Dal antigen.109 The discovery of this new 
antigen, along with the reports of cross-match incompatibilities observed between 
theoretically compatible typed dogs, suggests the presence of other canine blood types 
yet to be characterized, and highlights the importance of the crossmatching test.109 In 
humans, more than 50 high frequency RBCs antigens have been identified and defined as 
inherited antigens occurring in more than 90% of the population.127 However, a small 
group of related, usually sibling, individuals missing this antigen is at high risk for 
hemolytic reactions after an incompatible transfusion, as donors are not routinely 
screened for these antigens.127,128 According to a published report, the Dal antigen can 
potentially be included in this group. However, larger studies of the incidence of this 
  
 
 
Advances in canine transfusion medicine 
from the health of the donors to transfusion efficacy 
 
  
25 Chapter I – State of the art 
antigen in the general population will be needed so that it may be classified as a high 
frequency RBC antigen.109 In a published case report, a DEA 1.2 and DEA 4 positive 
Whippet developed delayed hemolytic transfusion reactions after two RBCs transfusions 
and an acute form after the third transfusion.125 By a series of pre- and post-transfusion 
crossmatchings with 14 full typed bloods, authors conclude that an alloantibody, other 
than DEA 1.1, 1.2, 3, 4, 5 and 7, was responsible for such reactions, and postulated that it 
could be related to a high frequency unknown antigen.125 Further studies are needed to 
clarify the existence and clinical importance of these high frequency antigens in dogs. 
However, failure to obtain a negative crossmatching with several universal donors should 
indicate that a highly frequent undiscovered antigen can be related. In such cases, 
siblings may potentially be compatible donors, considering that they are more probable to 
miss such antigen.125  
 
4.5 – Universal donor definition 
The definition of the canine universal donor is still not consensual.96,98 Considering 
that 98% of dogs are DEA 4 positive and that sensitized DEA 4 negative animals do not 
seem to develop acute hemolytic reactions after a second incompatible transfusion, some 
authors consider that DEA 4 positive and negative for every other DEA canine donors are 
universal donors.8,12,36,95,96 However there is a contradictory report of an acute hemolytic 
reaction in a dog that was DEA negative for all groups, after being transfused with a pRBC 
strictly DEA 4 positive.115 Other authors consider that, due to the low frequency of canine 
donors strictly DEA 4 positive (57.3% in Greyhounds and 28% in non-Greyhound dogs)122 
and the lack of evidence that other antigens incompatibility increases the risk of hemolytic 
reactions, DEA 1.1, 1.2 and 7 negative dogs should be considered universal 
donors.31,36,75,100 These authors excluded DEA 7 positive dogs from the universal donor 
pool due to the presence of natural antibodies against this antigen in DEA 7 negative 
dogs, the evidence of delayed hemolytic reactions in incompatible DEA 7 transfusions and 
the important incidence of this antigen in the canine population, higher than the DEA 3 
and 5 frequencies.95    
As previously stated, DEA 1.1 antigen seems to have the highest clinical relevance 
due to its strong antigenicity, capable of inducing severe hemolytic transfusion reactions 
at the second incompatible transfusion.97,100,126 These reactions are due to the production 
of a large amount of alloantibodies, immunoglobulin (Ig) G and M, from the ninth day after 
the first transfusion.97,100 Therefore, some authors consider that the routine typing of blood 
for other than DEA 1.1 antigen is unnecessary, since it is an expensive procedure and 
there are no evidences that it will decrease the overall risk of transfusion reactions.97,109 
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Thus, attending to these reports, 1.1 negative dogs should be considered “evidence-
based” universal donors in the first blood transfusion.95,97,109 
 
4.6 – Pretransfusion compatibility tests 
Red blood cells compatibility tests are the only available canine pretransfusion 
tests, being currently impossible to determine incompatibilities against antigens from other 
blood components such as leucocytes, platelets or proteins. These tests will detect both 
RBC membrane antigens and the presence of alloantibodies against RBCs, which allow to 
minimize the risk for hemolytic reactions and to extend transfused RBCs survival 
times.13,98     
 
Blood typing  
Blood typing allows for the identification of a specific antigen in the RBCs 
surface.9,36 Both blood donors and patients should be typed for DEA 1.1, the most 
clinically important antigen in dogs, and only compatible blood should be transfused as it 
avoids:12,25,36,55,75,96,100,108,126  
 delayed hemolytic reactions, even in a first incompatible transfusion, which are 
responsible for early RBCs destruction, decreasing their lifespan to 2-5 days; 
this premature RBC extravascular destruction, although non-symptomatic, may 
increase the need for subsequent transfusions, of particular importance in non-
regenerative anemias;  
 acute hemolytic anemias in pre-transfused and already sensitized patients with 
alloantibodies against DEA 1.1 antigen; 
 the risk of neonatal isoerythrolysis in puppies that have received DEA 1.1 
alloantibodies from a sensitized mother.  
 
Extended blood typing beyond this antigen seems to be indicated only when 
incompatible crossmatches between DEA 1.1 compatible blood samples are verified.96 
Three commercial rapid tests are currently available for in-clinic DEA 1.1 blood typing: 
DMS RapidVet-H®, Alvedia Quick Test DEA 1.1® and QuickVet®/ RapidVet®. The test card 
RapidVet-H® (Canine DEA 1.1) is based on an agglutination reaction between DEA 1.1 
positive RBCs, after interaction with lyophilized murine DEA 1.1 monoclonal antibodies. 
This test is accurate and allows for rapid identification of DEA 1.1, but it may also present 
weak agglutination reactions with blood from DEA 1.2-positive dogs.103,129 An important 
clinical advantage of this test is the fact that the agglutination reaction does not seem to 
be affected by lower PCVs.129 However, as the interpretation of the reaction involves 
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some subjectivity, this test should be used by trained technicians from laboratories or 
blood bank programs.129   
The Alvedia® Quick Test DEA 1.1® is an imumunochromatographic cartridge 
method that uses specific anti-DEA 1.1 monoclonal antibodies, incorporated in a 
membrane that will bind and retain DEA 1.1 positive RBCs during blood migration.129,130 
Thus, the presence of a red line in the membrane indicates the presence of DEA 1.1 
antigens, and the intensity of the color seems to directly correlate with the degree of 
expression of DEA 1.1 by RBCs and with the patient’s hematocrit.129,130 This method 
seems to be a suitable, easy to perform and to interpret rapid test.130 However, a false 
positive result in a dog with immune mediated hemolytic anemia (IMHA), typed by the gel 
column method (considered the “gold standard”109 but no longer commercially available) 
indicates the need for additional studies, particularly in animal affected by this disease.130 
In opposition, another study indicates this test as the best option for typing samples with 
persistent autoagglutination, without the need for RBCs washing procedures, since only 
free non-agglutinated cells are allowed to migrate up the strip to bind the test antibodies, 
being less sensitive to agglutination interference than other methods.129 Thus, according 
to Seth el al. (2012), the high specificity and easy interpretation make this test appropriate 
for use in emergency situations by non-trained personnel.129  
Recently, a new canine blood-typing method, the QuickVet®/RapidVet®, was 
developed by the Scandinavian Micro Biodevices Company. This system uses single use 
cartridges and an electronic analyzer, minimizing the user interpretation, but involves a 
higher initial investment.131 The system also uses a monoclonal antigen and agglutination 
is automatically interpreted by the analyzer. However, PCV of the samples have to be 
previously determined by the technician and values should be manually inserted in the 
electronic device, allowing for proper dilution with the reagent.131 Furthermore, samples 
have to be carefully evaluated, because severe hemolysis (leading to false-negative 
results) or agglutination (responsible by false-positive results) hampers the use of 
thismethod, according to the manufacturer’s instructions.131 One study compared the 
results obtained by this method with those from the gel column-base method, revealing a 
sensitivity of 96.2% and a specificity of 91.9%, concluding that, in spite of the 
discrepancies with the gel method (9/93, 9.7%), QuickVet®/ RapidVet® was suitable for in-
clinic blood typing, provided that strict preanalytical guidelines are followed and samples 
with inconclusive results are tested by other methods.131 
A previously discussed report, by the company Animal Blood Resources 
International, suggested that subgroups 1.1, 1.2 and 1.3 should not be interpreted as 
separate blood types, and that the results of rapid tests using monoclonal antibodies 
evidence different degrees of DEA 1 expression, identifiable by the interpretation of the 
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degree of agglutination or the intensity of the line on the Alvedia kits.105 Thus, the obtained 
results are essentially for DEA 1, and the named variables (1.1, 1.2 and 1.3) are simply a 
subjective determination of the agglutination reaction, not an identification of independent 
blood types.105  
Commercial tests for in-clinic evaluation of antigens other than DEA 1.1 are not 
currently available, so these determinations can only be performed in a specialized 
laboratory in the USA (Animal Blood Resources International, Michigan).109 No typing 
serum is yet available for DEA 6 and DEA 8, hampering the blood typing of these groups 
by any method.98     
 
Crossmatching 
While blood typing tests the RBCs for the presence of a specific surface antigen, 
crossmatching indicates the serological compatibility between donor and receptor, by 
testing the presence of natural or induced anti-RBC antibodies, either hemolysins or 
hemagglutinins.31,36 Thus, major crossmatching will detect antibodies against the donors’ 
RBCs present in the receptors’ plasma, while minor crossmatching allows to find 
antibodies from the donor, able to react with the receptors’ RBCs.31,36,132 A positive 
reaction in the major crossmatching, identified by the presence of hemolysis or 
agglutination, either macro or microscopically observed, predicts an acute hemolytic 
transfusion reaction and thus another blood donor should be used.11,31,36,98,132 Minor 
crossmatching is less relevant in pRBC transfusions, because the low volume of plasma 
in these units will rapidly dilute after infusion.12,31,36,132 Thus, it is rarely useful in dogs, 
unless a large quantity of plasma or WB from sensitized dogs is to be administered.31,98,132 
Additionally, crossmatching controls, that will test recipient and donors’ RBCs reactions 
with their own serum, should be performed, looking for the presence of 
autoantibodies.12,132,133 These tests should be held at 37°C, 25°C and 4°C because 
reactions are temperature-dependent.33 It is important to microscopically differentiate 
agglutination (similar to “clusters of grapes”) from rouleaux (“stacks of coins”), as they are 
indistinguishable macroscopically.11,44 Rouleaux are often technical artifacts, not indicative 
of the presence of alloantibodies, but they also can be related to the presence of high 
concentrations of abnormal globulins or fibrinogen.11,44 Blood samples with evident 
agglutination, positive results on crossmatching auto control or positive Coombs tests 
(direct antiglobulin test), indicate the presence of autoantibodies.11,98 In such cases, RBCs 
should be washed in saline in order to reduce the quantity of autoantibodies that are 
falsely indicating donor incompatibility.44,98 Moreover, agglutination of blood samples are 
usually related to cold reacting autoantibodies that can easily be inactivated by keeping 
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samples at a warm temperature, including the use of warm saline during the RBCs 
washing process.98  
Traditional protocols for both slide (most reliable) or tube agglutination reactions, 
have been widely reported in the veterinary literature.9,11,12,25,31,44,57,132-134 The lack of 
standardization of the procedure, along with time consuming protocols and subjective 
operator-dependent interpretation are important limitations of this traditional method.25,133 
Commercial in-clinic tests are recently available from two different companies. A 
gel crossmatch technology was applied in the Rapid Vet-H Companion animal crossmatch 
gel® test developed by DMS Laboratories, whereas the immuno-chromatography 
technique was used by Alvedia in the Lab test XM®. There are no published veterinary 
studies describing and comparing these methods but, considering the experience of the 
manufacturer laboratories, they should be considered faster and easier alternative 
methods when compared with traditional protocols. In addition, both techniques require 
smaller blood samples than a standard crossmatch (0.5 vs 2-3 mL) and can be used even 
with autoagglutinated samples.25 Besides, commercial tests do not require subjective 
interpretation of agglutination reactions and results can be reviewed at a later time. 
Crossmatching should be performed in the second and subsequent blood 
transfusions, even if DEA 1.1 compatible blood is being used and even if blood from the 
same donor is used in both first and second transfusions.34,36,44,57,58,109,132 There are no 
natural antibodies against the most antigenic and clinical important RBCs antigens, thus, 
before the first blood transfusion, crossmatching should always be negative even between 
bloods from distinct groups, unless an IMHA is present.34,36,57,58,109,132 In subsequent 
transfusions, if ≥ 4 days from the first have passed, crossmatching should always be 
performed, even between DEA 1.1 typed dogs, due to the possibility of allosensitization 
for other antigens than DEA 1.1.5,57,109,132 If a transfusion reaction occurred or was 
suspected in the first transfusion, crossmatching should be performed in every 
subsequent transfusion from the first day.25,109  
Despite its importance, crossmatching cannot substitute blood type determination 
because as there are no natural antibodies against DEA 1.1, in the presence of 
incompatible bloods crossmatching will always be negative in a first blood transfusion.98 
Besides, crossmatching has some limitations, like false negative results, due to low 
antibodies titers in some sensitized dogs, and inherent subjectivity in qualitative 
evaluations of agglutination reactions by traditional methods.31 
It is important to highlight that crossmatching does not prevent delayed hemolytic 
reactions, as antibodies will only be produced after RBC antigenic presentation, being 
inexistent or presented at very low titers before transfusion, at the time of the 
crossmatching test.44 Additionally, neither immunemediated reactions against leucocytes, 
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platelets or proteins, nor non-immunemediated reactions can be excluded with negative 
crossmatching tests, because only RBCs compatibilities are evaluated.44,98,132 Thus, it is 
extremely important to carefully monitorize transfused patients, even when RBCs 
compatibility tests are performed.98,132 
 
Antibody screen 
The antibody screening test aims to determine the presence of induced or natural 
alloantibodies in the receptor serum against RBCs antigens that may cause a hemolytic 
reaction.56,98,135 It is widely used in human medicine and requires the availability of RBCs 
of known phenotypes, able to react with the receptor serum.56,135 This pretransfusion test 
can be very useful in canine receptors with unknown previous history or at risk of 
possessing induced alloantibodies, allowing to select appropriate RBCs for transfusion 
that lack the antigen to which the receptor has developed antibodies.98 The main 
advantage of this test is that it avoids several crossmatchings with blood from potential 
donors in a pre-transfused sensitized receptor, as performed in some published clinical 
cases.124,125 Besides, it is impractical in the clinical setting to collect blood samples from a 
wide group of donors at the same time. Another potential application is the search of 
donors’ unexpected alloantibodies that could potentially react with the receptors RBCs 
after plasma or WB transfusion, although the clinical consequences of such reaction are 
debatable.13,56,98,113 Point-of-care tests are not available, and nowadays only one 
specialized laboratory in the USA is able to perform plasma antibody screening for anti-
DEA antibodies (Animal Blood Resources International) and blood typing for antigens 
other than DEA 1.1.  
 
 
5 – Packed RBCs transfusion 
 5.1 – Goals 
Packed RBCs transfusion avoids damages caused by tissue hypoxia in anemic 
patients. The main goal is to improve tissues oxygen delivery, keeping the patient in a 
stable condition while diagnostic and etiologic therapeutic procedures are being 
performed.69 Oxygen delivered (DO2) to organs depends on the blood flow (cardiac output 
- CO) and arterial oxygen content (CaO2), which is determined by the amount of Hb, its 
oxygen saturation degree, and the partial pressure of oxygen in the blood (PaO2).
36,71 
Arterial hemoglobin is responsible for approximately 98% of oxygen transport throughout 
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the body, and only 2% is dissolved in plasma.36 The following formulas are used to 
address factors related to tissue oxygen delivery:54,71 
 
DO2 = CO x CaO2, where CO = Heart rate (HR) x Stroke volume (SV) 
 
CaO2 (mL/L) = [% SatO2 x 1.39 (mL/g) x Hb (g/L)] + [arterial PaO2 x 0.0031] 
 
Thus, low cardiac output (stagnant hypoxia due to hypovolemia or cardiovascular 
compromise); low Hb saturation (hypoxic hypoxia, due to pulmonary disease); or low Hb 
concentration (anemic hypoxia) can be responsible for tissue hypoxia, and blood 
transfusions are indicated for the treatment of the last one, by improving Hb content.36,136  
 
5.2 – Indications 
Globally, pRBC units are indicated for clinically symptomatic normovolemic 
anemias that do not require coagulation factors.36,54,68 Specific indications for pRBC 
transfusions vary among studies and may be affected by geographic and temporal 
variations. Pathologies that have been suggested to benefit from pRBC transfusion are 
detailed in Table 6.  
 
Table 6. Reported pathologies that benefit from the administration of pRBC.
5,9,11,34,36,55,137-146 
Hemolysis Primary or secondary IMHA, pancreatitis, blood borne disease.  
Blood loss Postoperative anemia, perioperative splenectomy (with or without 
hemoabdomen), gastrointestinal bleeding (e.g. ulceration, foreign 
body, hemorrhagic gastroenteritis, parvovirus infection, gastric 
dilatation-volvulus), coagulopathy (e.g. anticoagulant rodenticide 
ingestion, hepatopathy, disseminated intravascular coagulation -DIC, 
hemophilia A, immune-mediated thrombocytopenia, von Willebrand 
disease - vWD, trauma, idiopathic hemothorax, uterine hemorrhage 
secondary to pyometra, internal or external hemorrhage from bleeding 
neoplasia, severe dental disease. 
Ineffective 
erythropoiesis 
Chronic renal failure, primary bone marrow dysfunction (aplasia, 
hypoplasia, myelopthisis) or secondary to neoplasia (Sertoli cell 
tumor, leukemia, lymphoma and multiple myeloma). 
 
A study performed by Stone et al. (1992) evaluated 291 WB and pRBC 
transfusions.5 The most frequent causes for transfusion were acute blood loss due to 
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trauma, surgery or bleeding tumors; anemia, most commonly due to IMHA or other 
hemolytic conditions; and bleeding due to coagulopathy associated with 
thrombocytopenia, DIC or vWD.5 A different study reviewed 163 pRBC transfusions 
administered to 131 dogs in 1989.55 Reasons to transfuse included anemia from blood 
loss in 70% of the cases; hemolysis in 22%; and bone marrow hypoplasia in 8%.55 In 
another retrospective study of 307 dogs submitted to RBCs transfusions, 72% where due 
to blood loss anemia (mostly related to trauma, surgery, neoplasia, thrombocytopenia, 
gastrointestinal bleeding and coagulopathy); 14% to hemolytic processes; and 14% due to 
ineffective erythropoiesis (including chronic renal failure, neoplasia and primary bone-
marrow diseases).140 This study also reported lower mean pretransfusion PCVs (13%) in 
the hemolytic cases, comparing to hemorrhagic (21%) or nonregenerative processes 
(18%). This fact could be explained by the clinician’s hesitation to administer RBCs to 
dogs with ongoing hemolysis in IMHA or by difficulties in obtaining a clearly safe result in 
blood compatibility tests.140 On the other hand, acute blood losses do not allow for an 
effective activation of hypoxic compensatory mechanisms and anemia signs may develop 
with higher PCVs.140 In other studies, reported frequencies of anemic etiologies ranged 
from 12-63% for hemolysis, 29-74% for hemorrhage and 8-34% for ineffective 
erythropoiesis.138,141,143,147 
 
5.3 – Anemia compensatory mechanisms  
In order to better define a transfusion trigger for pRBC administration, it is essential 
to understand the anemia compensatory mechanisms, including cardiovascular and 
metabolic responses, which allow patients to adapt and better tolerate low Hb 
concentrations. These include: 
 A decreased number of RBCs induces low blood viscosity that results in higher 
venous return and a decrease in the left ventricular afterload, responsible for 
increasing cardiac output.71 Hemodilution also improves blood flow in the 
microcirculation;54 
 The sympathetic stimulation increases ventricular inotropy and heart rate, which 
also contributes to increased cardiac output;54,136 however, severe tachycardia 
can be deleterious as it results in shorter diastolic times and subsequent 
reduction of myocardial perfusion by impaired coronary blood flow;136 
 The increased synthesis of 2,3-DPG enhances the ability of RBCs to release 
oxygen near tissues, by promoting a right-shifted oxyhemoglobin dissociation 
curve.54,136 Patients with chronic anemia may already have 2-3 times higher 
levels of 2,3-DPG;38  
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 Alterations in sympathetic tone induce peripheral vasoconstriction of the large 
veins, increasing blood return to the heart and consequently the SV. 
Additionally, a constriction of smaller arteries redirects blood flow to vital 
organs, thus facilitating coronary, pulmonary, renal and cerebral 
circulations;54,136 
 Vasoconstriction can also result in the mobilization of splenic blood reserves up 
to 50% of the sequestered blood volume.54  
 
As these mechanisms take time to establish, an acute decrease in PCV is often 
associated with sudden onset of clinical signs, unlike chronic anemias that are well 
tolerated.68,73 
 
5.4 – Transfusion triggers 
The transfusion trigger is the Hb level at which the decreased oxygen delivery is so 
reduced that anaerobic metabolism occurs, and it is used to describe a set of conditions 
under which transfusion is indicated.25,73 There are no established standardized guidelines 
for assessing whether humans or dogs benefit from a transfusion.44,147 However, several 
clinical and laboratory variables that may be useful in guiding the decision to transfuse 
have been described in dogs. Generally, RBCs replacement is necessary in the following 
conditions: 
 when PCV acutely drops to less than 20%;11,57,68,148  
 if PCV drops below 10%,36,57,68 as patients are at risk of multiple organ failure 
due to severe hypoxic injuries, or 20%,44,56 even in chronic anemias;  
 in cases of hemorrhage where more than 20%9 or 30%54,68,148,149 of TBV, 
according to different authors, is lost. Acute losses of 30-40% of TBV lead to 
shock with compromised organ function, and losses ≥ 50% lead to death if 
therapy is not instituted immediately;148  
 if a bleeding dog collapse;111,122 
 in ongoing non controlled hemorrhages;111,122 
 when PCV is < 18% with ongoing acute RBC destruction;9 
 in shock patients that are non-responsive to fluid therapy.68,148 
 
In a study involving healthy research dogs, oxygen uptake, mixed venous partial 
pressure of oxygen and oxygen delivery decreased significantly at PCVs below 10%.150 
Another experimental study of 30 healthy mongrel dogs with controlled normovolemic 
anemia, found that cardiac output and systemic oxygen consumption (VO2) were 
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maintained until PCV falls below 10%.151 However, it is possible that critically ill dogs with 
higher oxygen demands and/or compromise of either cardiovascular or respiratory 
systems may suffer from tissue hypoxia with higher PCVs. In fact, the decision to 
transfuse normovolemic patients, with no signs of organ dysfunction, will typically occur at 
much lower PCVs than to animals with hypovolemia, poor cardiac contractility, and/or 
respiratory compromise, because these patients require higher PCVs to maintain oxygen 
delivery.25,36,54 Other authors confirmed that PCV alone was not a predictive factor for 
transfusion requirements, as the overall clinical condition should be accessed and even 
considered the most important factor for the evaluation of transfusion needs.55,57,146 
Furthermore, following acute hemorrhage PCV may be normal, due to the simultaneous 
loss of RBCs and plasma, or even elevated, after splenic contraction.55,152 In the latter 
cases, PCV only starts to decrease after 2 hours, when intravascular fluid shifts and other 
compensatory mechanisms (e.g. increased antidiuretic hormone secretion or renin-
angiotensin-aldosterone system activation) result in plasma expansion and 
hemodilution.55,149   
Some authors advocate that blood transfusions should only be recommended if a 
patient is exhibiting clinical sings of anemia, such as tachycardia, bounding or week 
femoral pulse, pale mucous membranes, tachypnea, hypotension, cardiac arrhythmias, 
weakness, fatigue, hypothermia or collapse.36,54,57 However, the absence of abnormal vital 
signs should not exclude an ongoing hemorrhage, due to rapid activation of compensatory 
mechanisms. Occult hypoperfusion was described in human patients with blood loss and 
normal vital signs.153 Thus, some authors consider that dogs with active bleeding 
expected to quickly decompensate should also be serious candidates for early pRBC 
transfusion.39 One report found no correlation between HR and PCV in 173 dogs with 
IMHA, suggesting that the former should not be considered a sensitive indicator of occult 
tissue hypoxia in dogs with IMHA, highlighting the importance of assessing clinical signs 
as a whole.154 Such was the subject of two other publications where clinical signs of 
anemic patients were recorded and used as part of the decision-making process.55,147 One 
of them proposed a “transfusion-need scale” where point values were arbitrarily assigned 
to clinical signs and PCV determinations (Table 7).55 
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Table 7. Transfusion-need scale, suggested by Kerl et al. (1993).
55
 
PCV  Acute blood loss   
<13% 5 15% decrease in PCV  1 
13-15% 4 25% decrease in PCV  2 
16-19% 3 Anesthesia 2 
20-24% 2 Weakness 1 
25-34% 1 Tachypnea 1 
>34% 0 Tachycardia 1 
 
This scale was constructed by the retrospective characterization of 131 dogs submitted to 
pRBC transfusion and allowing to determine criteria to predict the need for pRBC 
transfusion.55 However, this scale heavily relies on the PCV, an unreliable indicator of the 
need for transfusion.147 Indeed, some limitations were found in the ability to identify blood 
transfusion needs in dogs with acute blood loss, as pretransfusion PCVs were presumably 
falsely elevated.55 Furthermore, weakness, respiratory and cardiac rates were 
misevaluated in anesthetized dogs.55 Authors also suggested that the volume of blood 
loss and blood pressure should be included in subsequent prospective studies.55 Another 
recent study proposed an “anemic dog clinical assessment score” (ADCAS) to assess 
transfusion needs by clinical parameters in a more objective and standardized approach 
(Table 8).147 
 
Table 8. Anemic dog clinical assessment score, suggested by Kisielewicz et al. (2014).
147
 
Score 0 1 2 3 
Mucous 
membranes color 
Salmon pink Slightly pale Moderately 
pale 
Severely pale 
Pulse quality Normal Bounding Weak Weak 
Heart rate 65-109 b.p.m. 110-140 b.p.m. > 140 b.p.m. > 140 b.p.m. 
Respiratory rate 15-24 r.p.m. 25-40 r.p.m. > 40 r.p.m. > 40 r.p.m. 
Mentation, 
exercise tolerance 
Normal, 
walking 
Quiet,  
able to walk 
Lethargic,  
able to stand 
Lethargic, 
Unable to 
stand 
 
In this study, 30 pRBC transfusions were prospectively evaluated. Pretransfusion ADCAS 
(ranging between 5 and 10) were significantly higher than post-transfusion ADCAS 
(ranging between 0 and 6), revealing the severity of the clinical signs prior to transfusion 
and the improvement of all scores after transfusion.147 This score remained unchanged 
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(same high scores) after transfusion in only three dogs, suggesting the need for further 
transfusions.147  
 Recent publications also described other laboratorial determinations, besides 
RBCs parameters, as potentially useful in transfusion decisions. A retrospective study of 
52 traumatized dogs (with blunt trauma) found higher transfusion requirements in those 
with lower base excess within the first 24 hours post-admission (admission base excess 
less than -6 was 88% sensitive and 76% specific for blood transfusion requirement).146 In 
fact, as traumatic hemorrhage leads to inadequate organ perfusion, tissue hypoxia 
increases anaerobic metabolism, and the negative base excess reflects the subsequent 
metabolic acidosis.153 Another important marker of tissue oxygenation is lactate as it 
directly correlates with hypoperfusion and hypoxia.147 In one study hyperlactatemia was 
found in 53% anemic patients before transfusion, and it decreased significantly in all 
patients within 1 hour post-transfusion, reaching physiological values in 25% of the 
dogs.147 Similarly, nearly 80% of anemic dogs presented venous oxygen contents (CvO2) 
< 5 mL/dL, that increased significantly after transfusion.147 This variable correlates directly 
with DO2 being a potential surrogate marker for tissue oxygenation.
147 Lactate predictive 
value was also evaluated in 129 dogs with IMHA that underwent pRBC transfusion within 
6 hours after admission.154 The authors found a significant decrease in their median 
lactate concentration (-1.9 mmol/L) after transfusion, a significantly superior change than 
the one registered in dogs not submitted to blood transfusions (-1.2 mmol/L).154 Although 
these laboratorial parameters seem to be of predictive value to identify animals in need of 
blood transfusion, no trigger values were suggested by the authors. 
In human medicine, transfusion triggers have been clarified on the basis of large 
prospective random clinical trials.  One study with 838 critically ill normovolemic patients 
concluded that transfusing a “restricted” (7 g/dL of Hb) versus a “liberal” (10 g/dL of Hb) 
group was considered safer practice, especially in patients who were less acutely ill and 
younger than 55 years of age. The mortality rate during hospitalization was significantly 
lower in the “restricted” group (20.5% vs 28.1% in the “liberal group”) with the only 
exception being patients with acute myocardial infarction and unstable angina pectoris.89 
The incidence of post-transfusion cardiogenic pulmonary edema and acute respiratory 
distress syndrome was significantly decreased in the “restricted” group strategy.89 Other 
prospective studies also found higher mortality rates in patients with those cardiac 
diseases that were transfused with Hb > 7 g/dL, versus Hb > 10 g/dL.90,155  
Important additional studies were performed in patients that refused to be 
transfused due to personal orientations. One study evaluated Jehovah’s Witness surgical 
patients who declined blood transfusions, and concluded that anemic patients with Hb 
below 6 g/dL had extremely higher mortality and morbidity rates, whereas 9.4% of patients 
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with postoperative Hb levels of 7.1 to 8.0 g/dL evidenced a morbidity event (e.g. 
myocardial infarction, arrhythmia).156 Another retrospective study revealed that an elective 
surgery can be safely performed in patients with a preoperative Hb level as low as 6 g/dL 
if the estimated blood loss is less than 500 mL.157 Similar results were reported in a case-
control study of 125 surgical patients who also declined blood transfusions for religious 
reasons.158 Results showed a higher mortality rate only for patients with Hb < 6 g/dL and 
for those that lost more than 2000 mL of blood during surgery.158 These studies suggest 
that mortality appears to depend on the surgical blood loss and preoperative Hb levels, 
and that both should be considered in assessing the need for preoperative transfusion. 
Also, surgical patients with Hb values above 10 g/dL do not seem to benefit from 
perioperative transfusion, those with 6-10 g/dL may have reduced morbidity without blood 
transfusion, and Hb values under 6 g/dL should be considered the cutoff for mandatory 
blood transfusion.159  
A theoretical model evaluated the relation between Hct and myocardial oxygen 
demand during acute normovolemic hemodilution, demonstrating that a transfusion trigger 
based in a fixed Hct is inadequate.160 Indeed, they reported different critical values, 
postulated for patients during the postoperative recovery phase:  14% Hct in patients with 
normal systemic oxygen consumption; 12% Hct  in cases of hyperoxia with arterial pO2 of 
400 mmHg; 21% Hct in patients with increased systemic oxygen consumption by a factor 
of three.160 Elderly patients (≥ 65 years old) with acute myocardial infarction were also 
evaluated and blood transfusions were associated with a lower short-term mortality rate if 
the Hct on admission was ≤ 30%.161  
These studies show that the decision to transfuse should be based on the degree 
of anemia, severity of the disease and comorbidities, rather than on a specific Hb 
concentration. Additionally, canine patients with cardiovascular compromise seem to be at 
higher risk and are more vulnerable to anemic hypoxia, requiring RBC transfusions at 
higher Hb concentrations.36,71 Thus, transfusion triggers should integrate references to the 
following:147,149 
 Clinical signs: depression, anorexia, tachycardia, tachypnea, hypotension, pale 
mucous membranes;56,147,149  
 Duration of the process: patients with acute anemia may have early 
decompensation, while those with chronic processes may be more tolerant to 
lower hematocrits;36,56,147,149    
 Rate of ongoing losses: since the Hct of patients with active hemorrhage are 
unreliable, arterial blood pressure and clinical signs should be used as 
transfusion triggers;149   
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 Underlying conditions: anemic patients with pulmonary or renal compromise, 
cardiovascular disease, hypovolemia or brain injury are less tolerant to anemia; 
such as in human patients, it is possible that elderly dogs should also be 
considered at risk, but this concept has not been supported yet;36,56,149,162  
 Systemic oxygen requirements: conditions like sepsis, systemic inflammatory 
response syndrome (SIRS) and DIC, or patients undergoing surgery, may 
benefit from higher oxygen delivery ability;149 
 Other analytical parameters: Lactate or base deficit seems to be of value as 
markers of anaerobic metabolism and transfusion needs; electrocardiographic 
abnormalities, such as S-T segment elevation or depression, may indicate 
myocardial ischemia.147,149,163,164 
 
5.5 – Packed RBCs benefits and efficacy 
The main purpose of transfusions is to restore the oxygen-carrying capacity to 
anemic animals, providing optimal tissue perfusion.36,149 Packed RBCs administration is 
the best available therapeutic option for such purpose, as it increases oxygen carrying 
capacity and improves blood circulation, by expanding intravascular volume and 
increasing oncotic pressure.165 The evaluation of the pRBC transfusion efficacy most 
frequently relies on the PCV increase of the receptor. Timing for post-transfusion PCV 
evaluation as an efficacy marker should be carefully selected, because the liquid fraction 
of the pRBC unit (AS, residual plasma and anticoagulant) may hide the amplitude of the 
receptor’s PCV elevation within the first hours after transfusion. Fluid shifting and 
reestablishment of intravascular volume can take up to 12-24 hours.149,162 However, earlier 
evaluation of post transfusion PCV avoids the influence of ongoing blood losses or 
hemolytic processes.69 One study evaluated the PCV one hour after pRBC transfusion in 
31 dogs, revealing a mean rise of 12.3% ± 6.1.69 Another study of 56 pRBC transfusions 
reported a smaller increase in the median PCVs from 14.7% (before transfusion) to 21% 
(12 hours post-transfusion).141 Although dogs with hemorrhage presented a significantly 
higher mean pretransfusion PCV (17%) than those with hemolytic anemias (8.6%) or 
ineffective erythropoiesis (10.1%), no significant differences were found in the mean 
increases of PCV between groups.141 
Clinical parameters were also reported to improve with RBC transfusions. An 
evaluation of 52 WB and 25 pRBC transfusions reported decreased heart and respiratory 
rates; decreased capillary refill times; rise of body temperatures; and improvement of the 
color of mucous membranes, 45 minutes after the start of transfusion.166 Overall better 
clinical condition was found within 2 hours.166 In another report, pulse rates and platelet 
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counts decreased significantly, and body temperature, MAP and PCV increased after 
transfusion of WB to 9 dogs.167 A recent prospective study of 30 dogs submitted to pRBC 
transfusions also found a significant improvement in the severity of the clinical condition, 
including mucous membranes color, pulse quality, heart rate, respiratory rate, mentation 
and exercise tolerance.147 A significant mean decrease of the post-transfusion HR (45 
b.p.m.) and respiratory rate (22 r.p.m.) was found. 147 Furthermore, the authors reported a 
decreased post-transfusion mean lactate concentration (0.6 mmol/L) and a significant 
increase of the mean hemoglobin concentration (3.6 g/dL), Hct (10.8%) and venous 
oxygen content (3.1 mL/dL).147  
 
Other benefits 
An important advantage of RBCs administration reported in humans is the 
potential to improve primary hemostasis. Red blood cells seem to stimulate platelets to 
produce thromboxane,  that facilitates platelet aggregation and reduces blood flow to the 
clot site, through vasoconstriction.168 Another platelet agonist, adenosine diphosphate 
(ADP), that causes platelet to change their shape and aggregate, is released by RBCs in 
response to endothelial injuries.169 RBCs may also induce the platelets dispersion from the 
center of the blood vessel toward the endothelial cells, facilitating their adhesion.169 These 
benefits have been widely recognized and led some authors to recommend, in the 
management of nonsurgical bleeding diathesis in thrombocytopenic patients, to increase 
Hct to 35% with pRBC transfusion before the administration of platelets.169  Indeed, some 
studies indicate a direct correlation between bleeding times and the Hct of anemic 
patients, with prolonged bleeding times being successfully reverted after pRBC 
administration.168-170  
Red blood cells are an excellent source of readily available iron, with 
approximately 1 mg of iron within 1 mL of pRBC.73 Thus, pRBC transfusions have this 
additional benefit in the treatment of severe iron-deficiency anemia.73   
 
5.6 – Packed RBCs transfusion reactions 
Before any blood component transfusion, its benefits and potential risks must be 
evaluated since, alongside with its potential lifesaving properties, transfusion may induce 
serious reactions. Transfusion reactions are defined as undesirable side effects resulting 
from the administration of a blood component, and are classified according to the 
involvement of the immune system and the duration of the process. Acute reactions occur 
within the first 24 or 48 hours post transfusion, while delayed reactions take place after 
this period.36,171,172  
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Transfusion reactions can be reduced by careful recognition of the transfusion 
triggers; selection of the optimal blood component; selection of blood donors; use of 
appropriate screening tests; and implementation of proper protocols for processing, 
storage and administration of blood components. However there will always be some risk 
associated with blood transfusions. Reported reactions are mostly mild and self-limiting, 
such as transient fever, vomiting and angioedema, but more severe reactions can also 
develop.31,36 To avoid the deterioration of clinical status and life-threatening events, the 
prompt recognition and immediate treatment of a transfusion reaction is crucial.36  
In one retrospective study of 131 dogs receiving pRBC transfusions, 13% 
developed transfusion reactions but all survived until discharge.55 Acute forms were seen 
in 59% of the reactions, manifested by vomiting, hemolysis and icterus, whereas delayed 
reactions, with a gradual decrease in PCV within a few days after transfusion and some 
with hemolysis or hematuria, were found in 41%.55 None of the reactions were fatal.55 
Some patients received more than one transfusion and no compatibility tests were 
performed, although only 1.1 and 1.2 negative blood units were used.55 A large 
retrospective study of 2078 blood components transfusions in dogs revealed a smaller 
frequency of transfusion reactions (3.0%), of which 92% were acute hypersensitivities or 
febrile reactions, 3.2% acute hemolytic and 4.8% delayed hemolytic reactions.132 Other 
studies reported different frequencies, ranging from 3.3% to 40% of overall pRBC 
transfusions.46,55,138,140,144 The highest published frequency was registered in a report of 15 
massive transfusions (where the 24 hours transfused volume was superior to the receptor 
TBV or the 3 hours transfused volume was superior to half of the receptor TBV), and 
included hemolysis, fever, vomiting and angioedema.144 The administration of high 
volumes of pRBC, along with the higher antigenic exposure associated with repeated 
transfusions, could justify such high rate – 40% of the receptors. Interestingly, studies of 
massive transfusions in humans failed to document an increased prevalence of post-
transfusion reactions.144,173 It is possible that some described reactions are associated to 
the original illness, misinterpreted by the retrospective analysis.144 Another study reported 
a high prevalence of transfusion reactions (37% of all transfused dogs) and suggested 
that clinicians are now more likely to monitor and register such reactions due to their 
increased awareness of complications in the latest years.44 The authors found a higher 
frequency of transfusion reactions in patients also transfused with other blood product 
(non-packed RBC) than with pRBC alone (50.7% vs 30.4%). Thus, the co-administration 
of large volumes of non-pRBC components was described as a risk factor for transfusion 
reactions.46  
In a report of 24 dogs with idiopathic immune-mediated hemolytic anemia receiving 
compatible pRBC transfusions, no clinically significant adverse reactions were identified 
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and no transfusion-related hemolysis was observed.142 Thus, hemolytic crisis do not seem 
to exacerbate after transfusions of pRBC, and there is no reason to avoid this life-saving 
therapy option, as empirically advocated by some clinicians. All reported transfusion 
reactions to date are described and classified in Table 9. 
 
Table 9. Classification and description of reported canine transfusion reactions. 
Acute immunologic reactions 
Allergic reactions25,174 
Definition and etiology 
Type I hypersensitivities, mediated mostly by IgE, caused by soluble substances within 
the donor plasma that bind to antibodies in the recipient, resulting in degranulation of 
mast cells and basophils with release of histamine, cytoquines and other vasoactive 
substances.25,36,174 Allergic reactions are mostly associated with plasma, platelet and 
WB transfusions.31,36,80  
Non-leukoreduced units can also induce allergic reactions by leukocyte degranulation 
during storage, followed by transfusion of vasoactive substances.80  
Reaction manifestations  
Usually within 45 minutes after transfusion starts.6,36 
Cutaneous signs: urticaria, pruritus, erythema, angioedema.6,25,80 Usually they are mild, 
self-limiting or easily treated.80 
Gastrointestinal and respiratory signs: vomiting, diarrhea, bronchoconstriction and 
hypotension.6,25,80 
Anaphylactic shock and cardiopulmonary arrest in severe cases.6,25 
Severity is directly proportional to the transfused volume.80 
Risk factors 
Plasma or platelet transfusions.171 
In humans: preexisting allergic conditions (e.g. atopy) seem to increase the risk.174 
Prevalence 
Anaphylactic reactions: in 2% of all registered pRBC transfusions.46 
Minor reactions (fever, facial edema, vomiting): 3.3% of pRBC and WB transfusions.140 
Hemolytic reactions 
Definition and etiology 
Acute reactions that develop due to the interaction between transfused RBCs and 
natural occurring or acquired alloantibodies, IgG (predominantly in dogs) or IgM, which 
activate the complement cascade resulting in a systemic inflammatory response - type II 
hypersensitivity.96   
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Reaction manifestations  
Intravascular hemolysis (within hours): hemoglobinemia, hemoglobinuria, 
vasoconstriction, renal ischemia and acute renal failure.6,96,100 A decrease in PCV is 
often associated.6,100,125  
Fever, restlessness, salivation, incontinence and shock.96,100 
Depression, recumbency, cardiac arrhythmia, apnea and seizures.6 
Patients may urinate or defecate, followed by tachypnea and tachycardia for a 
prolonged period of time.6 
DIC, multiple organ failure and death in severe cases.31  
Severity is directly proportional to the volume of blood transfused.80 
Risk factors 
Previous transfusions.171 
Prevalence 
Rare at the first transfusion in dogs, due to the absence of natural anti DEA 1.1 and 1.2 
antibodies.6,9,31,100 Higher prevalence in second mismatched incompatible transfusions, 
more than 72 hours after the first transfusion.6,9,31,100,125  
Nonhemolytic febrile reactions25,96 
Definition and etiology 
A 1-2°C temperature rise within 1-2 hours after a transfusion, with no other 
explanation.25,80,96 Usually induced by antibody reactions against donor leukocytes or 
platelets.25,96 More frequently associated with transfusion of platelet concentrates but 
also with any other products containing leukocytes or platelets (e.g. WB; non-
leukoreduced pRBC).80 
Leukoreduction filters can greatly reduce its prevalence, especially if used before 
storage of blood products.25,80  
Reaction manifestations  
Increase of 1-2°C, within 1-2 hours post-transfusion with no signs of hemolysis or 
sepsis.25,50,96 Pyrexia usually occurs within 30 minutes after the beginning of the 
transfusion and may last up to 8-20 hours.50,171 
Shivering, muscule rigidity and vomiting were also described.25,50 
Most reactions are benign and self-limiting,80 although some may cause hemodynamic 
or respiratory changes.96  
Risk factors 
Administration of units stored for a long period.171 
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Prevalence 
The most common in small animals.25,50,80,171 
Approximately 5% of transfusions performed at a veterinary teaching hospital.9 
Transfusion-related veterinary acute lung injury (TRVetALI)  
Definition and etiology 
A respiratory distress due to severe noncardiogenic edema, developed within 24-48 
hours post-transfusion, but typically evident within the first 1-2 hours.71,96,175 Leucocytes 
antibodies from donors, which can react with recipient neutrophils, seem to play an 
important role in this phenomenon, along with a nonimmune insult to the pulmonary 
vascular endothelium, responsible for capillary leak.176  Mostly associated with multiple 
plasma transfusions.176 In humans, a high risk is associated with units collected from 
females with previous pregnancies.176  
Reaction manifestations  
Clinical presentation is similar to acute respiratory distress syndrome (ARDS) or acute 
lung injury (ALI): tachypnea, fever, tachycardia and hypoxemia with no evidence of 
circulatory overload.25 
It is mainly a diagnosis of exclusion, and clinician should rule out circulatory overload, 
cardiogenic pulmonary edema, hemolytic reactions, bacterial contamination and 
anaphylactic reactions.80,177 
It is difficult to distinguish whether a patient has TRVetALI or non-transfusion-induced 
VetALI, because underlying inflammatory disease processes (e.g. infection, pancreatitis 
or postsurgical inflammation) or DIC are risk factors for VetALI, as well as a common 
complication in critically ill patients, independent of the administration of blood 
products.46,175    
TRALI is self-limiting and humans usually recover within 96 hours, with a reported 
mortality rate of 5-10%.26,80,177  
Prevalence 
It is the major cause of transfusion-related mortality in humans, and 0.014-0.08% of 
critically ill patients develops TRALI.177,178 
Rare syndrome in companion animals.80 An incidence of 3.7% of pRBC transfusions 
was reported in a study with 54 dogs receiving pRBC, WB and FFP transfusions.175 
Transfusion-related immunomodulation (TRAMI) 
Definition and etiology 
A transient modulation of the immune system following transfusion, related to the 
immunosuppressive  or  proinflamatory properties  of  blood components.179,180 Although 
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not fully elucidated, the mechanism seems to be multifactorial, including: a functional 
reduction of natural killer cells and macrophages; an increased suppressor T-cells 
activity; a reduced helper T-cells activity; a down-regulation of the cellular immunity; and 
a decreased hematopoiesis.54,179,181  
Reaction manifestations  
Increased risk of cancer recurrence; postoperative infection; virus activation; and 
multiple-organ failure.54,181 However, it is unclear whether these complications are 
transfusion-associated or transfusion-induced.181 
Risk factors 
Administration of non-leukodepleted RBCs or units stored for a long period.179,180    
Prevalence 
Not described in animals. 
Delayed immunologic reactions 
Immune-mediated hemolysis 
Definition and etiology 
This reaction is based on the production of anti-RBCs IgG by the receptor, shortly after 
transfusion, resulting in extravascular removal of the transfused RBCs – type II 
hypersensitivity.6,96,182 Dogs develop antibodies within 3-14 days post-transfusion, and 
these remain detectable for years.80,98,182  
Reaction manifestations  
Clinically undetectable mild reaction, often masked by an hemolytic underlying 
disease.80 
Extravascular hemolysis with splenic removal of antibody-coated RBCs and progressive 
increase in serum bilirubin.80,182  
Post-transfusion PCV rapidly decreases within 3-5 days after transfusion.96 Transfused 
RBCs normal life span severely reduced from 21-48 days to 2-5 days in some 
patients.6,55,108 This premature removal of transfused RBCs has more clinical relevance 
if the regenerative ability of the recipient is compromised.95  
Prevalence 
Frequent in a first mismatched incompatible transfusion for DEA.1.1 and 1.2.6 
More common than acute hemolytic reactions.33 
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Post-transfusion purpura 
Definition and etiology 
Exposure to transfused foreign platelets antigens (whole or fragments) present in units 
of WB, pRBC, platelet concentrate or platelet-rich plasma during the second 
transfusion, in sensitized animals, may lead to platelets destruction by an unknown 
mechanism, with subsequent thrombocytopenia.180,183  
Reaction manifestations  
Thrombocytopenia 7-14 days post-transfusion, potentially leading to spontaneous 
bleeding.80,183 It can be self-limiting after several weeks.183 
Prevalence 
Rare in dogs.171,183  
Neonatal isoerythrolysis 
Definition and etiology 
A hemolytic anemia that develops in neonates after ingesting colostrum with DEA 1.1 
antibodies.184 It only occurs if a sensitized DEA 1.1 negative bitch, that received 
previous incompatible transfusions for this antigen, feeds DEA 1.1 positive puppies.184 
Reaction manifestations  
Hemolytic anemia after 3-10 days of nursing.184 
Weakness, failure to thrive, hemoglobinemia and hemoglobinuria.184   
Prevalence 
Not reported. 
Serum sickness 
Definition and etiology 
A type III hypersensitivity induced by donor antigens interaction with recipient 
antibodies, resulting in the formation of intravascular immune complexes.182 Deposition 
of such complexes may be potentially harmful in several tissues due to complement 
activation and induced inflammatory response.182  
Reaction manifestations  
Vasculitis, synovitis, arthalgia, myalgia, fever, lymphadenopathy, glomerulonefritis and 
neuritis.182 Clinical signs typically develop 1-3 weeks after transfusion.182 
Prevalence 
Not reported. 
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Acute nonimmunologic reactions 
Sepsis 
Definition and etiology 
Induced by bacterial contamination of blood components, mostly originated from the 
venipuncture site; subclinical donor bacteremia; or contamination during 
administration.36,43,96,185 The most common isolated agents are the gram negative 
organisms Yersinia, Serratia and Pseudomonas able to multiply at cold 
temperatures.43,96,185  
Reaction manifestations  
Endotoxic shock often manifests by fever, hypotension, DIC and renal failure.12 
Bacterial related pyrexia can develop within 15 minutes after the start of the 
transfusion.50 It can be accompanied by other signs such as abdominal pain, vomiting, 
diarrhea, hemolysis, DIC, multi-organic dysfunction syndrome (MODS) and shock.50,171 
Risk factors 
Transfusion time over 4 hours.25,34,36,43,54,68,149 
Platelet products stored at room temperature.171  
Administration of units collected in open systems, with air exposure.12,43,44,68 
Use of improper collection, processing and administration techniques.43,68 
Prevalence 
One of the most common causes of transfusion-related morbidity and mortality in 
humans.96 
Not reported in dogs.  
Citrate toxicity: hypocalcemia 
Definition and etiology 
Unmetabolized citrate, the mostly used anticoagulant in commercial blood collection 
systems, chelates the recipient ionized calcium, inducing hypocalcemia.50,52,96 
Most common in massive transfusions, when large volumes of FFP or WB are 
transfused rapidly.50,52,96 As citrate effects are dose and rate dependent, extremely rapid 
infusion may also induce hypocalcemia.52 
Since citrate is predominantly metabolized in the liver to bicarbonate, severe hepatic 
disease can compromise citrate metabolism, being considered a risk factor.50,52,80 
Effects of citrate are also formulation-dependent, and CPD seems to cause a larger 
decrease in canine ionized calcium than ACD formula.186 
Reaction manifestations  
Tremors, tetany, nausea, vomiting and hypotension.36,50,80 
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Cardiac arrhythmias (mostly ventricular arrhythmias), bradycardia and prolongation of 
the Q-T interval.36,52,149,187 
Hypotension and decreased cardiac output, associated with lower systemic vascular 
resistance and cardiac contractility.52 
Alkalosis secondary to the renal citrate metabolism.52 
Prevalence 
Scarcely reported. Massive transfusions in 10 dogs induced hypocalcemia, with 
extremely low values in two cases.144 Only one dog evidenced clinical signs.144  
Rare in small animals.171 
Hypomagnesemia 
Definition and etiology 
Unmetabolized citrate, the mostly used anticoagulant in commercial blood collection 
systems,  binds to magnesium, decreasing its availability in massive transfusions.144  
Reaction manifestations  
Similar signs to those described in hypocalcemia, including muscle spasms and cardiac 
arrhythmias.144 It may exacerbate signs in hypocalcemic patients.144 
Prevalence 
Reported in nine dogs submitted to massive transfusions.144 
Transfusion-associated circulatory overload (TACO)  
Definition and etiology 
Blood products may cause a significant oncotic pull, more pronounced in those 
containing albumin (WB and FFP), that can potentially lead to volume overload when 
excessive volumes are administrated, especially in normovolemic patients.25 Rapid 
administration is also an important cause of circulatory overload.80,96  
Reaction manifestations  
Pulmonary edema or pleural effusion: tachycardia, dyspnea, cyanosis, orthopnea, 
coughing.25,50,80,96 
Hemodilution and serous nasal discharge.25 
Increased central venous pressure (CVP) and/or arterial blood pressure (ABP).80,96 
Risk factors 
WB transfusions, neonates, underlying cardiopulmonary disease, oliguric or anuric renal 
failure.50,80,96,171 
Prevalence 
Relatively common in small animals.50  
 
  
 
 
Advances in canine transfusion medicine 
from the health of the donors to transfusion efficacy 
 
  
48 Chapter I – State of the art 
Table 9. cont’d. 
Hyperammonemia 
Definition and etiology 
Ammonia concentration increases with time in stored canine pRBC, mainly due to 
deamination of adenine and proteins (from plasma or RBCs).36,94 Transfused old pRBC 
with high ammonia concentration does not induce hyperammonemia but its 
administration to patients with hepatic compromise, or those receiving massive 
transfusions, may increase the risk of hyperammonemia and encephalopathy.36,94  
Reaction manifestations  
Ataxia, dementia, head pressing, circling, seizures, vomiting.36,171 
Risk factors 
Hepatic dysfunction and aged RBCs administration.171 
Prevalence 
Not reported. 
Hypothermia 
Definition and etiology 
Hypothermia can occur from rapid infusion of large volumes of cold units, especially if a 
central venous catheter is used.80,96,144 
Reaction manifestations  
Hypothermia, ventricular arrythmias and coagulopathies.80,96,144,171 
Risk factors 
High volumes, high rates of administration, small or pediatric patients, use of central 
venous catheters.69,119,149,153  
Prevalence 
After massive transfusions, 69% of 13 dogs developed hypothermia.144 
Hyperkalemia 
Definition and etiology 
Caused by leakage of potassium after RBC lysis, mainly due to ATP decrease during 
storage, but also by inappropriate collection, processing or administration techniques, 
along with bad storage conditions.7,54 
Reaction manifestations  
Bradycardia and cardiac arrhythmias.7 
Prevalence 
Rare, except in cases of pre-existing renal failure or hyperkalemia.54 With the exception 
of a few canine Asiatic breeds like Akitas (unsuitable as blood donors),188 dogs are 
unique  in  having  RBC  lacking  substantial  concentrations  of potassium,  making  this 
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reaction less common than in humans.11,41,144 
Nonimmune-mediated hemolysis 
Definition and etiology 
Destruction of donor RBCs before transfusion, induced by improper processing or 
storage; bacterial contamination; inadvertent freezing; and mishandling during 
administration by using blood-warming devices, hot water baths or 
microwaves.31,36,43,68,96,189 Mechanical injuries during collection or transfusion techniques 
can also be responsible for shear injuries to RBCs, caused by clogged filters, tubes or 
needles, twisty or narrow tubes and small bore needles or catheters.64,189 Osmotic 
hemolysis may happen with concurrent administration of drugs or hypotonic solutions in 
the same catheter.6,68,96 
Reaction manifestations  
Clinical signs similar to acute hemolytic reactions, either during or shortly after 
transfusion: hemoglobinemia, hemoglobinuria, rapid decrease of PCV, fever, prolonged 
coagulation times, thrombobocitopenia, petechiae and ecchymosis, melena, 
hematemesis and progressive dyspnea.189   
Reactions are usually benign and require no treatment.31 A contradictory study reported 
acute life-threatening transfusion reactions in four dogs, with three fatalities, after the 
administration of hemolyzed pRBC units due to inappropriate storage.189 A recent study 
suggested that transfusing older RBCs (42 days of storage) appears to result in high 
free-Hb concentrations and non-bound iron content, increasing the risk of shock and 
lung injury, with a high mortality rate, in dogs with severe pneumonia.190 No significant 
risks were demonstrated in non-infected dogs.190 Similar results were obtained in a 
previous study with massive transfusions of older stored blood to dogs with induced 
pneumonia.191  
Prevalence 
Not reported 
Dilutional coagulopathy 
Definition and etiology 
Coagulopathies due to dilution of clotting factors and platelets due to transfusion of 
large volumes of pRBC (platelet-free or with nonfunctional platelets).54,96,144  
Reaction manifestations  
Thrombocytopenia and prolonged coagulation times, increased risk for bleeding 
episodes.144 
 
  
 
 
Advances in canine transfusion medicine 
from the health of the donors to transfusion efficacy 
 
  
50 Chapter I – State of the art 
Table 9. cont’d. 
Prevalence 
In one report, 15 dogs that underwent massive transfusion developed moderate 
thrombocytopenia, three of them evidencing markedly prolonged coagulation times.144 
No hemorrhages were reported.144  
Air embolism 
Definition and etiology 
It can occur when blood in an open system is infused under pressure or if air enters 
through a central catheter. A large amount of air needs to be infused to induce clinically 
significant complications.184 In humans, infusion of 100 mL of air is potentially fatal.192 
Reaction manifestations  
Cough, dyspnea and shock.184 
Prevalence 
Rarely reported.36 
Delayed nonimmunologic reactions 
Transmission of infectious diseases  
Definition and etiology 
Diseases transmitted by blood components that were improperly tested before 
transfusion.50 
Reaction manifestations  
Clinical signs associated to the transmitted infectious agent.17-21  
Prevalence 
Unknown. Some case reports were published.17-21 
Hemochromatosis 
Definition and etiology 
Massive infusion of RBCs in the absence of blood loss leading to storage of 
administered iron in excess (hemosiderin).36,193 Mostly described in human patients with 
refractory anemias, including pure red cell aplasia, aplastic anemias and leukemias.194  
Reaction manifestations  
Hemosiderin accumulation within the hepatocytes cytoplasm, leading to hepatic failure 
and MODS in most severe cases.193  
Increased serum iron, ferritin, total iron-binding capacity and iron saturation.193  
Prevalence 
Rare.171 One single report of hemochromatosis in a dog with pure red cell aplasia, after 
receiving WB transfusions every 6-8 weeks for 3 years.193  
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5.7 – Mortality rate and risk factors 
Several studies described the mortality rate of dogs transfused with pRBC. In a 
retrospective study of 131 dogs, only 62 (47%) survived to hospitalization,55 while one 
other reviewed  474 pRBC and 184 WB transfusions to 307 canine patients and verified 
that nearly 61% were discharged from the hospital and, from those that died, only three 
where euthanized due to financial constraints of the owners.140 Mortality rate in a 
retrospective analysis of 211 dogs submitted to pRBC transfusion was 30.8%, including 
4.3% spontaneous deaths and 26.5% euthanasia.46 Other published mortality rates in 
pRBC transfused dogs ranged between 29% and 73%.114,116,119 Considering that patients 
receiving pRBC transfusions usually have serious underlying diseases, such high 
mortality rates are not surprising and surely not solely attributable to the transfusion 
consequences.140  
High pretransfusion PCVs and high volumes of transfused pRBC were identified as 
risk factors for death before discharge, suggesting a potential benefit of a conservative 
transfusion strategy in dogs.46 However, such findings were not confirmed by other 
studies.140 Interestingly, neither the occurrence of a transfusion reaction nor the mean age 
of pRBC units were considered risk factors for survival, although the small number of 
aged units administered compromised the statistical power of the study.46  
No significant differences were found in the mortality rates between the three 
causes for anemia (blood loss, hemolysis and ineffective erythropoiesis), although 
patients with hemangiossarcoma tended to have the worst prognosis.139-141,144 
 
5.8 – Packed RBCs administration 
Recommended volume 
Several formulas have been published in the veterinary literature to predict the 
transfusion volume needed to achieve the desired post-transfusion PCVs. A study with 31 
anemic dogs concludes that the most accurate formulas for such purpose were:69 
 
Volume (mL) = body weight (kg)*[(desired PCV - start PCV)/ donors’ PCV]*90  
 
Volume (mL) = 1.5*desired rise in PCV (%)*body weight (kg)  
 
The desired PCV should be the minimum required for appropriate oxygen delivery, 
patient stabilization and management of the clinical condition, rather than to restore the 
normal PCV.34,73,182 The described target PCVs are 25-30% in hypovolemic blood loss and 
20% in chronic anemias or immune-mediated hemolytic anemias (avoiding suppression of 
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erythropoiesis).11,68,73 These are merely indicative values, expected to vary depending on 
the patient’s primary disease and comorbid factors.73,182  
In spite of the accuracy of these formulas, some authors tend to simplify the 
recommended pRBC volumes, indicating 10-15 mL/kg as the quantity of a therapeutic unit 
with AS.12,36 Dogs with IMHA often require multiple transfusions and higher volumes of 
pRBC  due to ongoing hemolysis of both native and transfused RBCs (24 mL/kg, versus 
17 mL/kg in hemorrhagic patients).140  
Some authors advocate that the administration of more than 22 mL/kg/day should 
be avoided, as it can precipitate hypocalcemic tetany or hypocoagulable states.11   
  
Administration technique  
The process of the transfusion influences the RBCs survival.6,25  Therefore, a 
proper technique is mandatory in order to maximize the transfusion efficacy and reduce 
the risk of a transfusion reaction.6,25 The following procedures constitute the currently 
accepted state of the art on canine pRBC transfusions:    
 Heating pRBC units. Blood products should be warmed before administration 
by letting them rest at room temperature to avoid patient hypothermia and to 
decrease blood viscosity.6,149 Any warmed bag must be used within 24 hours, 
thus preventing bacterial growth.6,11 Components for very small or young 
patients, more prone to hypothermia, can be actively warmed to a temperature 
that must not surpass 37°C, using a warm-water bath or by passing the 
infusion system thru a tube heater.149 Excessive heating decreases the 
oxygen-carrying capacity of RBCs, increases bacterial growth in contaminated 
units, induces precipitation of fibrinogen and promotes the degradation of 
coagulation factors and proteins.7,36,54 Moreover, RBCs heated over 40°C 
suffer irreversible membrane damages that result in impaired deformability and 
increased osmotic fragility, leading to extravascular hemolysis.195 Microwaves 
should not be used because of potential excessive heating and non uniform 
heat distribution.25 
 Catheters and administration routes. Since resistance to blood flow is 
inversely proportional to the catheter diameter and directly proportional to its 
length, wide (< 22 gauges, ideally 16-20 gauges) and short peripheral 
catheters should be used and aseptically placed.11,43,68,149,182 Any intravenous 
(IV) catheter that has been used for more than 24 hours should be replaced 
before the transfusion, ensuring a strict aseptic technique administration.11 
Ideally the cephalic or jugular veins should be used but, in severely 
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hypotensive or in pediatric patients, blood can be infused intramedullarly thru a 
needle placed in the femoral trochanteric fossa, the greater tubercle of the 
humerus or the tibial crest.6,11,36,196 Intraperitoneal administration is scarcely 
used since transfused cells have a shorter life span and only 50% of the 
infused RBCs enter the circulation within the first 24 hours and 70% within 48-
72 hours.11,197  
 Transfusion systems. A dedicated IV fluid line should be used for blood 
components administration, along with an IV set with filter (typically 170 μm) 
that removes potentially harmful blood clots, cellular aggregates, fat and 
microthrombi.6,7,11,34,36,54,149 One filter may be used to administer 2-4 units of 
blood to the same patient, within a maximum time limit of 4 hours because 
accumulated material may slow the administration rate and room temperature 
may predispose to proliferation of contaminating microorganisms.73 Care 
should be taken when connections between the catheter, the transfusion 
system and the pRBC unit are performed in order to avoid contamination and 
maintain a closed system (e.g. no air exposure).12,44  
 Administration rate. The initial transfusion rate must be slow (0.25 mL/kg/h in 
the first 30 minutes), allowing for the monitorization of acute 
reactions.11,34,36,54,149 If no adverse effects are noted, the rate can be increased 
to 5-10 mL/kg/h.1151,125 In patients with hypovolemic shock, initial higher rates 
(up to 22 mL/kg/h) can be used.11,36 Inversely, in patients with renal or cardiac 
compromise at higher risk of volume overload, rates under 4 mL/kg/h are 
advocated.11,36 Such rates, however, increase the risk of bacterial 
contamination of the unit, as transfusions often last more than 4 
hours.7,25,34,36,43,54,68,149  
 Simultaneous fluid administrations. Blood products must not be infused 
through the same catheter with calcium-containing medications or fluids 
because calcium binds and deactivates the citrate anticoagulant solution, 
potentially leading to the formation of thrombus.11,36,68,149 Likewise, hypotonic or 
glucose-containing fluids should be avoided due to their hemolytic potential 
from osmotic fluid shifts.11,33,36,68,149   
 Patient monitorization. Vital signs need to be evaluated every 15 minutes 
during the first hour and every 30-60 minutes thereafter.25,34,54  Any signs of 
transfusion reaction must be identified and properly addressed.34,54,149 In 
animals under anesthesia many of these signs may be difficult to recognize, 
but unexplained hypotension or tachycardia and excessive operative 
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hemorrhages suggest ongoing reactions.149 A control PCV must be obtained 1-
2 hours after the cessation of the transfusion and patients should be evaluated 
for transfusion reactions during the following 24 hours.54 
 
Another important aspect of blood components transfusion is the use of automatic 
pumps. In the search for optimized delivery techniques, three different options for blood 
administration were recently evaluated: gravity, volumetric pump and syringe pump.198 
The authors concluded that the use of mechanical devices was significantly related to the 
short survival of RBCs. Upon the use of syringe pumps and volumetric pumps, there was 
respectively a 14% and 50% probability for a complete destruction of the transfused cells 
within 24 hours.198 Since these higher losses were not related to different osmotic 
fragilities of the used pRBC units, the authors postulated that shearing stress, caused by 
forcing blood through the filters of automatic devices, may result in RBCs damages with 
their consequent removal by the reticuloendothelial system of the receptor.198 Thus, the 
authors concluded that the gravity method is recommended as it avoids this early 
destruction of RBCs.198 However, in small canine patients an accurate control of the 
administration rate and delivered volumes, based in drops counting, can be difficult to 
achieve. In such receptors, the risk of transfusion-associated circulatory overload should 
be counterbalanced with the risk for early loss of transfused RBCs.  
 
 
6 – New perspectives in blood transfusion medicine 
6.1 – Red blood cell substitutes and adjunctive therapies  
Oxyglobin® is a sterile Hb-based oxygen-carrying solution made from purified 
bovine hemoglobin and licensed in some countries, recommended for the treatment of 
anemic dogs.57,199 There are no canine RBC antigens in this product, thus there is no 
need for blood typing or crossmatching.200 The recommended dosage is 15-30 mL/kg of 
body weight, depending on the degree and chronicity of the anaemia, and the desired 
duration of its effects.200 A pharmacokinetic analysis concluded that the administration of 
30 mL/kg increases the recipient Hb by 3.6-4.8 g/dL, and that a minimum 1 g/dL rise will 
last for 74-82 hours.200 Oxyglobin® must be administered intravenously at a rate up to 10 
mL/kg/h.200 Due to its high osmolarity (300 mOsm/L), care should be taken in patients with 
cardiopulmonary or renal compromise.57,200 Additionally, the possibility of circulatory 
overload and pulmonary edema should be considered especially when adjunctive IV fluids 
are simultaneously infused.200 Other reported adverse effects include vomiting, anorexia, 
and fever.200 Another interesting aspect is that, due to its plasma expansion properties, 
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Oxyglobin® administration results in a mild short-term decrease in PCV.200 After infusion, 
the product induces serum and urine discolorations that may seriously compromise 
biochemical colorimetrical readings used for coagulation profiles and urine dipstick 
measurements, but no interference on hematology analysis was found.200 An abnormal 
color of mucous membranes can also be detected, although it does not affect pulse 
oximetry.201   
The metabolism of the infused Hb follows the normal pathways, through 
dissociation in plasma and progressive incorporation in the protein pool of the organism, 
whereas the heme group is also degraded into bilirubin and bile pigments.200 
Although the intact product has a long shelf-life (3 years), an open bag must be 
used within 24 hours to avoid bacterial contamination and Hb oxidation to methemoglobin, 
unable to bind oxygen.200,202 The manufacturer also recommends that Oxyglobin® must 
only be used once per animal.200  
In order to assess the efficacy of this product, 64 dogs with moderate to severe 
anemia (PCV 6-23%) where randomized for either treatment with Oxyglobin® or no 
treatment.203 Ninety five percent of dogs treated with Oxyglobin® did not need additional 
oxygen-carrying support for 24 hours, whereas in the untreated group, 68% needed 
additional support such as pRBC transfusion.203 There were no observable allergic 
reactions.203 One other study with eight splenectomized Beagles, evaluated the repeated 
IV administration of Oxyglobin® at 1.3 g/kg, nine times over 50 weeks.204 Results 
evidenced the presence of specific IgG antibodies by week 6, but this humoral immune 
response did not decrease the oxygen-binding capacity of Oxyglobin®.204 Furthermore, 
there was no increased risk of anaphylactic reaction to infusion and thus repeated 
administration was considered safe in dogs, contradicting the manufacturer 
recommendations.204 One study in eight experimental Beagles found no adverse effects 
on the renal structural integrity in dogs undergoing complete isovolemic blood exchange 
with Oxyglobin®.205 Another prospective study of 12 dogs suffering from anemia caused by 
natural infection with Babesia rossi demonstrated the efficacy of Oxyglobin®. Post-
treatment alterations of blood gases, acid-base status and blood pressures were similar to 
dogs submitted to pRBC transfusions, although the latter had a faster return to normal 
appetite and attitude (24 hours versus 72 hours in the Oxyglobin® group).206  
Oxyglobin® is a very promising product as it increases oxygen content in the blood 
more efficiently than RBC Hb, being able to deliver 3-4 times more oxygen.199 Additionally, 
its strong colloidal and pressor effects can help in the management of hypotensive cases, 
like in sepsis or SIRS, whereas its lower viscosity potentially improves the blood flow 
facilitating tissue perfusion.199,202 Besides, Oxyglobin® advantages of this solution also 
include the absence of transfusion reactions, decreased risk of transmission of infectious 
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diseases, increased storage time and no need for refrigeration.200,203,205,206 However, 
compared with transfused allogenic RBCs, it has a markedly shorter half-life, limiting its 
use specially in nonregenerative anemias.201 Moreover, the high cost (approximately 335 
€/250 mL) makes this treatment unaffordable in most cases.   
Administration of exogenous recombinant human erythropoietin (rhEPO) may 
also be of value in the treatment of anemic patients. In humans, the administration of 
rhEPO to anemic ICU patients significantly decreases the percentage of patients in need 
of blood transfusion (45%, compared with 55% of patients in the placebo group),207 with 
no differences in mortality or frequency of adverse reactions between the two groups.207 
No studies were performed with anemic canine receptors, although the pre-collection 
administration of rhEPO to canine autologous blood donors prevents the post-collection 
decrease in their hematocrit.208 The high cost of rhEPO is, however, a limiting factor for its 
clinical application in canine patients.  
 
6.2 – Cell salvage devices  
Cell salvage is a technique by which bloodshed is collected, washed and re-
administered to the patient.193 The use of automatic devices in this procedure has recently 
been considered as very useful in canine autologous blood transfusions, since it can be 
applied to re-infuse blood collected from massive bleeding in a surgical field or through a 
surgical drain, such as in cardiotomy or hemoperitoneum.209,210 One other potential 
therapeutic application is plasmapheresis for the treatment of autoimmune diseases.209 
The technique was well described by Kellett-Gragory et al. (2013). Aspirated blood passes 
through a filter, that removes tissue fragments and eliminates small air bubbles, and it is 
collected into a centrifugation bowl where RBCs are separated from plasma proteins 
(supernatant) and lighter cellular elements (buffy coat), both discarded into the waste 
bag.209 After a washing process with 0.9% saline solution, the obtained RBC concentrate 
reaches a 60% Hct and is reinfused into the patient by a system with an in-line 
leukoreduction filter that reduces bacterial load and virtually eliminates still present 
leukocytes and malignant cells.209,210  
Contraindications include contamination of the collected blood with solutions that 
promote hemolysis, such as hypotonic fluids, hydrogen peroxide and alcohol.210 When 
correctly processed, salvaged RBCs are equal or superior to banked blood in terms of 
osmotic resistance, morphology, pH and levels of 2,3-DPG.211 The main obstacle to its 
application is its limited access and high cost. Moreover, the recent growth in blood 
banking, with the consequently increased availability of blood components, reduced the 
need for autotransfusion in the most recent years.54 
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6.3 – Leukoreduction filters  
Leukoreduction filters are widely used in human practice to reduce leukocyte 
concentration from collected blood units. This process can be performed either before 
storage (prestorage filtration), thus eliminating the potential deleterious effects of white 
blood cells (WBCs) on RBC viability during storage, or immediately before administration 
(bedside filtration), avoiding transfusion reactions related to the leukocytes activity.66,141  
In dogs, WBCs able to induce: 1) febrile nonhemolytic reactions due to 
inflammatory mediators released by WBCs apoptosis during storage or due to 
alloimunization against leukocytes and platelets;184,212 2) pulmonary microembolism 
caused by WBC aggregates formed during storage;176 3) hemolysis of the pRBC unit due 
to the release of metabolites such as cytoquines, histamine or serotonin by the lysis of 
leukocytes during storage;213,214 4) decreased RBC survival by depletion of glucose 
associated with the leukocyte activity in stored units.215   
A recently published study evaluated the inflammatory responses to canine stored 
pRBC transfusions and the effects of prestorage leukoreduction.66 Thirteen large breed 
dogs were randomly divided into two groups to whom an autologous leukoreduced or non-
leukoreduced pRBC unit, collected 21 days before, was re-infused.66 The filtration process 
of cooled WB units (4°C during four hours) effectively eliminated 99.79% of WBC and 
99.98% of platelets, whereas only 3.2% RBC where retained in the filter.66 After 
transfusion, there was evidence, in the group receiving non-leukoreduced pRBC units, of 
marked increases in total WBC counts, fibrinogen and C-reactive protein levels, 
suggesting that such changes of the inflammation markers were associated with the 
presence of leukocytes and/or platelets in stored units.66 Another study published similar 
results regarding the effectiveness of this leukoreduction process.65 The advantage of pre-
cooling the WB units before filtration was evidenced by Brownlee L et al. (2000) who 
demonstrated that the processing of non-cooled WB units allows for depletion of only 
88.9% of the total WBCs and that an important volume of the blood (approximately 50 mL) 
is retained by the filters.65  
In vivo PTV studies indicate that 84.7% of RBCs from leukodepleted units stored 
for 35 days retained their viability 24 hours after infusion.65 This value is similar to 
previously published results with non-leukodepleted units,28 not only suggesting that 
RBCs are not adversely affected by the filtration process,65 but also that the putative 
improved storage conditions of leukodepleted pRBC units do not result in higher RBCs 
PTV and subsequent longer shelf-lives.  
A retrospective study of 56 canine pRBC transfusions, performed with bedside 
leukoreduction filters, reported a very low rate of transfusion reactions (2%), when 
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compared with non-leukoreduced pRBC transfusions,141 as previously demonstrated in 
humans.216-218  
Another important advantage of these filters is their ability to remove 75-100% of 
contaminating bacteria.219 In one study where pRBC units were inoculated with Yersinia 
enterocolitica, the number of positive cultures after 42 days of storage was much smaller 
in prestorage leukoreduced units (8%) than in non-leukoreduced units (67%).220 According 
to Graf et al. (2012) dogs with cancer may also benefit from the administration of 
leukoreduced heterologous components, as filters seem to be effective in preventing the 
release of vascular endothelial growth factor (VEGF), upon disintegration of platelets and 
WBCs during the storage of canine pRBC and FFP, a pro-angiogenic factor that 
potentially favors the metastatic spread of cancer.221 Another recent study also described 
a significant reduction of IL-8 in pRBC units stored for 28 and 35 days when prestorage 
leukoreduction is performed, when compared with non-leukoreduced units, potentially 
reducing the proinflammatory effects of the transfusion of stored pRBC.81 
Despite the reported potential advantages, some studies failed to demonstrate the 
benefits of the use of leukoreduction filters in the outcome of receptors.205,206 Furthermore, 
the universal use of leukodepleted pRBC units is still controversial in human practice.222 
The use of leukoreduction filters in veterinary practice is also influenced by their price as 
the transfusion cost will increase nearly 35 €, a value that is still cost-prohibitive in many 
critical cases, especially when attending to the lack of evidence-based advantages.71,73  
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This thesis aims to contribute to the clarification of several aspects related to 
canine transfusion medicine, in order to increase the safety of the collection process to 
blood donors, to establish good practices of processing and storage of canine pRBC units 
and to increase the safety and effectiveness of pRBC transfusions.  
 
Specific objectives: 
 
Collection process – ensuring safety and welfare  
1. To evaluate the hemodynamic effects of blood collection from sedated and non-
sedated dogs and to understand if those effects were volume-dependent.  
2. To evaluate the bone marrow regenerative response and iron status of canine 
frequent donors submitted to one and two years of repeated blood collections. 
 
Whole blood processing and storage of pRBC – best practices and quality control 
programs  
3. To evaluate the quality of pRBC units based on their final volume, PCV, total Hb 
concentration, haemolysis and presence of aerobic and anaerobic bacterial 
contamination, and to search for their relationship with the collection and 
processing techniques. 
4. To evaluate the hemolysis of canine pRBCs stored with SAG-MAN, and to 
address its association with storage time, duration of the collection process, 
collection disturbances, and the pRBC units volume, PCV and initial hemolysis.  
 
Packed red blood cells transfusion – associated risks and benefits  
5. To identify the prevalence of DEA 1.1 in Portuguese dogs and its relationship 
with phenotypic characteristics in order to analyze the risk of untyped blood 
transfusions. 
6. To identify the main causes of anemia and clinical signs that lead practitioners 
to use pRBC transfusions, to evaluate the benefit of such transfusions, the 
associated outcome and to determine the incidence of adverse reactions.  
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1 – Blood collection effects on canine donors 
 
1.1 – Volume-dependent hemodynamic effects of blood collection in canine 
donors - evaluation of 13% and 15% of total blood volume depletion. 
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Abstract 
Background: There is no consensus regarding the blood volume that could be safely 
donated by dogs, ranging from 11% to 25% of its total blood volume (TBV). No previous 
studies evaluated sedated donors. Aim: To evaluate the hemodynamic effects of blood 
collection from sedated and non-sedated dogs and to understand if such effects were 
volume-dependent. Materials and Methods: Fifty three donations of 13% of TBV and 20 
donations of 15% of TBV were performed in dogs sedated with diazepam and ketamine. 
Additionally, a total of 30 collections of 13% of TBV and 20 collections of 15% of TBV 
were performed in non-sedated dogs. Non-invasive arterial blood pressures and pulse 
rates were registered before and 15 minutes after donation. Results: Post-donation pulse 
rates increased significantly in both sedated groups, with higher differences in the 15% of 
TBV collections. Systolic arterial pressures decreased significantly in these groups, while 
diastolic pressures increased significantly in 13% of TBV donations. Non-sedated groups 
revealed a slight, but significant, SBP decrease. No clinical signs related to donations 
were registered. Conclusion: These results suggest that the collection of 15% of TBV in 
sedated donors induces hemodynamic variations that may compromise the harmlessness 
of the procedure, while it seems a safe procedure in non-sedated dogs.   
 
Introduction 
In the latest decades, canine transfusion medicine has been receiving a growing 
attention, with particular emphasis on blood components therapy, transfusion triggers, 
compatibility, and transfusion reactions (Gibson and Abrams-Ogg 2012, Mathews et al. 
2006, Schneider 1995). However, health and welfare of blood donors is scarcely 
mentioned in scientific studies. Consequently, there is currently no consensus on the ideal 
frequency of donations, the blood volumes that can safely be collected or the effects of 
sedation in such procedures. Previously published studies vary both in volume and 
frequency of donations. Proposed protocols include the collection of volumes ranging from 
10 to 22 mL/kg every 21-28 days without any nutritional supplement (Ford and Mazzaferro 
2006, Gibson and Abrams-Ogg 2012, Mathews et al. 2006, Schneider 1995) or every 10-
21 days with iron supplement (Authement 1991). According to these data, and assuming a 
TBV of 85-90 mL/kg (Post 2000), 10 to 25% of TBV can be collected in each procedure. 
The depletion effects were identified as an immediate post-donation decrease of the 
systolic blood pressures of non-sedated donors submitted to the collection of 17-22% of 
TBV (Couto and Iazbik 2005). To authors’ knowledge, this was the only clinical study 
performed in canine blood donors addressing hemodynamic effects, however it only 
studied Greyhounds, which have a lot of specific physiologic peculiarities that hampers 
extrapolation of results to other breeds. In humans, the Council of Europe recommends up 
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to four blood donations per year in men and up to three in women, with a maximum 
volume of 13% of TBV (Council 2011), while the United Kingdom Blood Transfusion 
Services recommend a maximum of three yearly donations for both genders (UK 2005). 
Differences between both species could be related to a donation-related vasovagal 
reaction (VVR), a very important adverse effect in humans with reported prevalences 
ranging from 0.87% to 7% (Newman 2004, Newman et al. 2003, Zervou et al. 2005). The 
vasovagal reaction, a complex and still incompletely understood mechanism, results in 
cardio inhibitory and vasodepressive effects (Trouern-Trend et al. 1999) that can be 
associated with the hypovolemic state induced by volume depletion, the orthostatic 
hypotensive effect, as well as the associated psychological stress caused by fear of 
needles, pain and the sight of blood (Wieling et al. 2011). In dogs, only volume depletion 
can be related to VVR, because the quadruped position prevents the orthostatic effect, 
which could explain why dogs have lower incidences of VVR, hence tolerating the 
collection of higher blood volumes.  
Due to the less than optimal behavior of some canine donors, blood banks face 
two options: either to eliminate such animals from the donation program or to sedate them 
in order to proceed according to the best and safest methods. The first option results in a 
significant loss of resources, while the second allows for a better planning of the program 
and for the use of the safest and more efficient methods, both in order to guarantee the 
quality of the final product but also, and foremost, the comfort and safety of the donor.  
It is known that sedation has hemodynamic effects, namely inotropic and 
chronotropic, that, when combined with the blood depletion inherent to the procedure, 
may risk the donor welfare and health. However, to the authors’ knowledge no studies 
were performed in sedated blood donors.   
Our study aimed to evaluate the hemodynamic effects of blood collection from 
sedated dogs and to understand if such effects were volume-dependent. Since the 
combined effects of sedation and blood depletion had never been evaluated, the authors 
refrained from collecting large volumes of blood. Therefore, volumes were chosen on the 
basis of the maximum recommended for human blood banks (13%) and the value more 
often described in the veterinary literature (15%).  
 
Materials and methods 
The study protocol was approved by the ICBAS-UP Ethics Committee (Project 
number 008/2012) and an informed consent was obtained from each owner. All animals 
were mixed-breed healthy 1-7 years old dogs, weighing 21-45 kg, that had been 
vaccinated, dewormed and had normal complete blood count parameters and serum 
values of alkaline phosphatase, alanine aminotransferase, creatinine, total proteins and 
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glucose. Furthermore, they all had negative Polymerase Chain Reaction analysis for 
Anaplasma spp., Ehrlichia spp., Babesia canis, Leishmania infantum, and Dirofilaria 
immitis. If it was required, canine donors unable to keep still were sedated and randomly 
submitted to the collection of 13% of TBV (group 1) and 15% of TBV (group 2). Non-
sedated dogs were also randomly selected to donate 13% (group 3) and 15% of TBV 
(group 4).  
Physical exam and measurement of arterial blood pressures were performed 
before each procedure, after placing the donors in lateral recumbency over the donation 
table. Donors from groups 1 and 2 were sedated with diazepam 0.5 mg/kg, IV (Valium, 
Roche®) and ketamine 5 mg/kg, IV (Clorketam, Vetoquinol®), administered over one 
minute using a catheter placed in the cephalic vein. In both sedated and non-sedated 
dogs the puncture site over a jugular vein was clipped of hair and aseptically prepared 
(chlorhexidine and alcohol). These procedures lasted less than 5 minutes and were 
followed by jugular venepuncture allowing the blood to flow by gravity into the collection 
bag. The total collected volumes were calculated on the basis of the dogs’ weight, 
assuming that canine TBV is 85 mL/kg (Jahr et al. 2008) and that 1 mL of WB weights 
1.053 g (Kakaiya et al. 2011). Once the total volume was obtained, the collection tube was 
sealed. Within 15 minutes after blood collection, capillary refill times (CRT), pulse rates 
and arterial blood pressures were re-evaluated. From collection to discharge, all dogs 
were qualitatively monitored for changes in mental status and activity levels, and after 
discharge owners were requested to report any abnormalities within the next 48 hours.  
Non-invasive systolic arterial pressure (SAP) and diastolic arterial pressure (DAP), 
were evaluated by the oscilometric method (Dinamap Carescape V100, General 
Electrics®) in the metatarsal artery, with dogs in lateral recumbence in the donation table 
on a quiet non-stressful environment, using cuff widths that were equivalent to 40% of the 
leg diameter where the measurements were made. Mean arterial pressures (MAP) were 
automatically calculated by the equipment. The first value was discarded and the seven 
subsequent measurements were registered, if deemed consistent (less than 20% 
variation). Abnormal readings caused by unexpected movements were also discarded. 
The mean of each pressure was calculated from five registered measurements, after 
rejection of the lowest and highest values. Pulse rates were measured by digital palpation 
of the femoral arteries during 60 seconds. CRT was measured on the labial mucosa.  
Results were analyzed using SPSS statistical software.  Normal distribution of data 
was assessed with the Kolmogorov-Smirnov test.  Paired sample Student’s t-test was 
used to compare differences between measurements of pulse rate, SAP, MAP and DAP 
registered before and after each blood collection. One-way ANOVA was used to compare 
the group differences of the post-donation values. Specific significant differences between 
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each group were identified by a post hoc Bonferroni test. The critical probability for 
statistical significance was taken to be p ≤ 0.05. 
 
Results  
Complete data from 123 blood collections were registered, including 83 dogs 
donating 13% of TBV (53 sedated and 30 non-sedated) and 40 dogs donating 15% of 
TBV (20 sedated and 20 non-sedated). The collection procedures lasted less than 15 
minutes, sedation recovery times ranged between 40 and 70 minutes and all dogs went 
home within 3 hours after collection. No donation-related clinical signs were evident in the 
hospital nor reported by the owners. CRT was ≤ 1 second in all measurements.   
Pre- and post-donation values for each variable were normally distributed and are 
presented in Table 1 and Figures 1-3.  
 
Table 1. Pre- and post-donation pulse rates, SAP, MAP and DAP.  
 Pre-donation Post-donation t value  p value 
 M SD M SD   
Group 1 (N=53)       
p.p.m. 116.09 18.70 154.62a,b 30.82   -9.583      0.000 
DAP 86.43 16.65 93.28c 17.55 -3.099 0.003 
MAP 107.04 15.33 111.58d 19.22 -2.009 0.050 
SAP 145.88 15.35 139.61 21.35 2.674 0.010 
Group 2 (N=20)       
p.p.m. 117.40 17.56 183.65a,e 32.61 -8.469 0.000 
DAP 80.20 10.23 82.85 10.86 -0.762 NS 
MAP 103.80 8.45 101.05 12.39 0.813 NS 
SAP 141.10 9.84 131.85 16.69 3.902 0.001 
Group 3 (N=30)       
p.p.m. 117.53 21.39 120.33b 25.24 -0.529 NS 
DAP 84.01 15.10 82.50c 16.36 0.592 NS 
MAP 105.75 15.90 99.33d 16.18 3.165 0.004 
SAP 141.74 18.99 127.53 21.57 7.073 0.000 
Group 4 (N=20)       
p.p.m. 119.85 15.38 111.60e 24.28 1.476 NS 
DAP 77.75 10.97 73.05 11.43 1,248 NS 
MAP 99.30 11.29 91.55 13.66 3.661 0.003 
SAP 142.65 11.78 123.15 17.02 8.611 0.000 
M – mean; NS– non significant.
 a 
p = 0.001; 
b 
p < 0.001; 
c
 p = 0.017; 
d
 p = 0.010; 
e 
p < 0.001 
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In groups 1 and 2 there was a small, albeit significant, post-donation reduction of 
the mean systolic pressures (SAP), accompanied by a small increase of the mean 
diastolic pressures (DAP), that reached significance in group 1. Significantly higher post-
donation pulse rates were observed in both groups, with the mean of group 2 surpassing 
180 p.p.m. and in 30% of the collections surpassing 210 p.p.m.. In the non-sedated 
groups (groups 3 and 4), only SAP decreased significantly, with no significant variation of 
the pulse rates. When comparing the post-donation values of sedated dogs, group 2 
presented significantly higher pulse rates than the remaining groups.  
 
Figure 1. Mean pulse rates evidenced before and after the blood collection on each group.  
 
 
Figure 2. Mean SAP values evidenced before and after the blood collection on each group.  
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Figure 3. Mean DAP values evidenced before and after the blood collection on each group.  
 
 
 
Discussion   
This study aimed to evaluate the hemodynamic effects of blood depletion in 
sedated and non-seated canine blood donors, and to understand if its amplitude was 
volume-dependent.  
 Ketamine is a fast acting general anesthetic and analgesic that induces anesthetic 
stages I and II (Plumb 2005). Its cardiovascular effects are due to an increased 
sympathetic tone and include higher cardiac output, heart rate, aortic, pulmonary artery, 
and central venous pressures, while its effects on total peripheral resistance have been 
described as variable (Lysa and Posner 2009, Plumb 2005). Diazepam is frequently 
added to ketamine, in order to provide good muscle relaxation and add sedative and 
anxiolytic effects (Lysa and Posner 2009, Plumb 2005). This is a fast-acting, short 
duration combination, with no cardiopulmonary depressant effects, that produces 
adequate relaxation and immobility (Lysa and Posner 2009, Plumb 2005).  Furthermore, 
the absence of hypotension effects or peripheral vasoconstriction, frequently associated 
with other sedative agents, facilitates the blood collection process, ensuring very good 
venous access which allows a quick and easy procedure. Other sedative agents that had 
been described for use in blood collections include butorphanol (Mathew and Abrams-ogg 
2006), hydromorphone (Lester 2012, Mathew and Abrams-ogg 2006), acepromazine 
(Mathew and Abrams-ogg 2006) and dexmedetomidine (Lester 2012). Although 
butorphanol has analgesic properties and induces central nervous system depression in 
dogs, it may reduce HR and decrease arterial blood pressures, by increased 
parasympathetic tone (Plumb 2005). Hydromorphone has analgesic and sedative 
properties but may induce respiratory depression, bradycardia, vomiting and constipation 
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(Plumb 2005). Acepromazine has important hypotensive effects and should be avoided to 
minimize post-donation hypotension (Mathew and Abrams-ogg 2006, Plumb 2005). 
Dexmedetomidine, an alpha-2-adrenergic agonist, causes a profound peripheral 
vasoconstriction that, when associated to its negative chronotropic and inotropic effects, 
hampers adequate blood collection by decreasing blood flow velocity (Lysa and Posner 
2009). One limitation of our study is the lack of a control group with animals subjected to 
the used sedation protocol without blood collection. However, the inclusion of such group 
would be ethically unacceptable. 
Although none of the dogs in this study experienced clinical consequences of the 
procedure (e.g. depression, weakness, pale mucous membranes or increased capillary 
refill time), some important facts deserve attention and must be considered in practice. 
Post-donation pulse rates increased significantly in groups 1 and 2 but this phenomenon 
was particularly marked in the group where 15% of TBV was collected, reaching very high 
frequencies (183.7; SD 32.7). Furthermore, 30% of the dogs in this group reached 
frequencies above 210 p.p.m., a value that was never observed in sedated animals that 
donated 13% of TBV nor in any non-sedated donor. Considering that the collection 
procedures were pain-free, the authors believe that the sympathetic-stimulant effects of 
ketamine were the main contributors to these positive chronotropic responses, when 
superimposed to higher blood volume depletions. Rapid heart rates increase myocardial 
oxygen demands and reduce cardiac output and coronary blood flow by shortening the 
diastolic period, potentially increasing the risk for development of occult tachyarrhythmias 
(Olgin and Zipes 2012). Thus, based in our results, it seems that the collection of volumes 
≥ 15% of TBV in sedated animals, may be considered a risky procedure that should be 
avoided whenever possible.  
Post-donation mean SAP was slightly but significantly lower in all groups, when 
compared to the pre-donation values, with a decrease being found in two thirds of the 
collections in group 1 and 80% of the collections in group 2. Systolic arterial pressure is 
related to the left ventricular stroke volume, which in turn is highly dependent on preload 
(Egner 2003). Therefore, the reduction of SAP is probably a direct consequence of the 
blood volume depletion. Furthermore, at the high cardiac rates induced by both blood 
depletion and ketamine effect, the decreased diastolic duration results in less ventricular 
filling (preload) with subsequent lower stroke volumes (Olgin and Zipes 2012). Our post-
donation SAP variations are similar to those previously published in non-sedated blood 
donor Greyhounds (Couto and Iazbik 2005). 
The ketamine sympathetic-stimulant effects lead to an increased peripheral 
vascular resistance (Egner 2003) that partially compensates for the blood depletion 
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effects by increasing the DAP. However, this compensation seems to be limited since the 
post-donation increase of DAP was only significant in dogs from group 1.  
It is important to highlight the large variability of arterial blood pressure values. It is 
known that individual responses to blood depletion depend on different sympathetic tones, 
as well as on different pre-donation anxiety states. Two dogs experienced non-
symptomatic mild to moderate hypotension after blood collections (SAP 77-97 mmHg; 
DAP 51-57 mmHg), one from group 1 and one from group 2. These values were 
considered to represent mild to moderate hypotension, according to published reference 
values of hypotensive episodes in awake dogs (mild: SAP/DAP < 100/60 mmHg; 
moderate: < 90/50 mmHg) (Egner 2003). In humans, a SAP lower than 75 mmHg may 
lead to a syncopal episode (Trouern-Trend et al. 1999) but, to the authors’ knowledge, no 
studies addressed such correlations in dogs. Post-donation measurements were 
performed with dogs still under the sedative effects and none demonstrated clinical signs 
after recovery from sedation. This could be due to the stress-related secretion of 
catecholamine (Egner 2003) during the euphoric state after full recovery from sedation, 
which may increase arterial blood pressure. A previous study demonstrated that when the 
animals return to a standing position after blood donation in lateral recumbency, there was 
a rapid increase of arterial blood pressure (Couto and Iazbik 2005), supporting our 
hypothesis.  
Overall, our results suggest that it is safe to collect up to 13% of TBV in canine 
donors sedated with ketamine and diazepam and that the collection of higher volumes 
could induce hemodynamic variations that may compromise the harmlessness of the 
procedure.  
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Resumo 
Atualmente não existe consenso relativamente ao volume de sangue que pode ser 
recolhido com segurança em cães doadores, variando de 11% a 25% do seu volume total 
de sangue (VTS) de acordo com os autores. Até ao momento nenhum estudo prévio 
avaliou o efeito das doações de sangue em animais sedados. O objetivo deste trabalho 
foi avaliar os efeitos hemodinâmicos da recolha de sangue em animais sedados e não 
sedados, e compreender se esses efeitos eram dependentes do volume de sangue 
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recolhido. Foram realizadas 53 doações de 13% do VTS e 20 doações de 15% do VTS 
em cães sedados com diazepam e ketamina. Adicionalmente, um total de 30 recolhas de 
sangue de 13% do VTS e 20 recolhas de 15% do VTS foram realizadas em cães não 
sedados. Antes e 15 minutos depois das doações de sangue, foram registadas as 
pressões arteriais, medidas de forma não invasiva, e a frequência do pulso. Após as 
doações realizadas por cães sedados, as frequências do pulso aumentaram 
significativamente, mas de forma mais intensa nas recolhas de 15% do VTS. A pressão 
arterial sistólica diminuiu significativamente nas doações de 13% e 15% do VTS dos 
animais sedados, enquanto a pressão arterial diastólica aumentou significativamente nas 
doações de 13% do VTS. Os cães não sedados revelaram apenas uma diminuição da 
pressão arterial sistólica. Após a doação nenhum animal desenvolveu sinais clínicos. 
Estes resultados sugerem que as recolhas de 15% do VTS em dadores sedados induzem 
alterações hemodinâmicas que podem comprometer a segurança deste procedimento, 
enquanto em cães não sedados as dádivas parecem não ter efeitos deletérios.   
Palavras-chave: cão, doação de sangue, sedação, volume. 
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1.2 – The effects of repeated donations on the iron status and hematologic 
parameters of canine blood donors. 
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Supplementary data  
 
Effects of repeated blood donations over a period of 2 years on the iron 
status and hematologic variables of canine blood donors 
 
Introduction 
After the previous study, some owners agreed to maintain their animals in the 
blood donor program, enabling their evaluation during a period of 2 years, thus allowing 
for a more prolonged study of their iron status after frequent blood collections. 
 
Material and methods 
Donors from group 1 were not further evaluated. During the two year period, 11 
dogs (8 females and 3 males) were submitted to the collection of 13% of TBV (11.4 
mL/kg) every 3 months (group 2) and 11 dogs (4 females and 7 males) to collection of 
15% of TBV (13.2 mL/kg) every 3 months (group 3). Protocols for collection, sample 
evaluation and statistical analysis were similar to the previous study.  
 
Results 
A total of 198 blood collections were performed, including 99 from donors in group 
2 and 99 from group 3. All variables were normally distributed throughout the study. The 
initial and final iron status biochemical parameters are presented in Table 1. No significant 
differences were found.  
Mean pre- and 10 days post-collection hematology values are evidenced in Table 
2. In both groups a significant increase in MCV, RDW, PLT, WBC and reticulocytes 
percentage was found 10 days after the colection, but there were no differences between 
groups.  
There was a positive correlation between the number of collections and both RDW 
values (Pearson correlation coefficient -group 2: r = 0.23 and p = ≤ 0.05; group 3: r = 0.63 
and p < 0.001) and reticulocyte percentages (Pearson correlation coefficient – group 2: r = 
0.35 and p < 0.001; group 3: r = 0.62 and p < 0.001), indicating an adaptation of the bone 
marrow to the blood depletion along the 2 years in both groups.  
The comparison of final hematology values, measured 10 days after the last 
donation, evidenced that dogs from group 3 had a significantly higher mean RDW than 
those from group 2 (p ≤  0.001) (Table 3).  
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Table 1. Mean ± SD values for iron status biochemical variables for dogs before inclusion in a 
blood donor program (initial) and after the final blood collection in 11 dogs donating 13% of TBV 
every 3 months (group 2), 11 dogs donating 15% of TBV every 3 months (group 3) for 2 years. (p > 
0.05). 
Group Variable Initial Final 
2 Iron (μg/dL) 135.00 ± 30.43 152.91 ± 60.20 
 Ferritin (ng/mL) 168.45 ± 65.50 148.09 ± 29.87 
 Transferrin (mg/L) 381.14 ± 45.84 370.45 ± 70.21 
    
3 Iron (μg/dL) 131.54 ±  34.83 151.23 ± 43.85 
 Ferritin (ng/mL) 144.46 ± 36.55 147.23 ± 45.39 
 Transferrin (mg/L) 382.87 ± 84.10 370.73 ± 114.82 
 
Table 2. Mean ± SD values of hematologic variables before and 10 days after blood collections in 
11 dogs donating 13% of TBV every 3 months (group 2), 11 dogs donating 15% of TBV every 3 
months (group 3) for 2 years. 
Group Variable Before collection After collection 
2 PCV (%) 46.20± 4.77 46.30 ± 4.24 
 Hb (g/L) 164.72± 20.25 164.21 ± 15.97 
 RBC count (X 106 cells/μL) 6.38 ± 0.85 6.70 ± 0.74 
 MCHC (g/L) 346.15 ± 22.52 341.63 ± 2.59 
 MCV (fL) 71.59 ± 3.43 74.02 ± 4.07* 
 RDW (%) 13.06 ± 1.69 13.90 ± 1.92† 
 Platelet count (X 103 platelets/μL) 238.28 ± 75.84 284.00 ± 76.33† 
 WBC count (X 103 cells/μL) 8.85 ± 2.66 9.67 ± 2.27* 
 Reticulocytes (%) 0.28 ± 0.20 1.18 ± 0.61† 
    
3 PCV (%) 47.57 ± 4.31 47.37 ± 3.99 
 Hb (g/L) 169.21 ± 15.75 166.67 ± 14.43 
 RBC count (X 106 cells/μL) 7.04 ± 0.70 6.92 ± 0.66 
 MCHC (g/L) 337.94 ± 37.84 335.99 ± 16.41 
 MCV (fL) 70.26 ± 3.39 71.59 ± 3.44* 
 RDW (%) 15.45 ± 2.16 16.35 ± 2.40† 
 Platelet count (X 103 platelets/μL) 220.07 ± 76.94 259.28 ± 91.09† 
 WBC count (X 103 cells/μL) 8.10 ± 2.26 9.29 ± 2.63† 
 Reticulocytes (%) 0.22 ± 0.15 1.25 ± 0.55† 
            *,†Within a row, values differ (*p ≤  0.05; †p ≤  0.001) significantly. 
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Table 3. Mean ± SD values of hematologic variables measured 10 days after the last blood 
collection in 11 dogs donating 13% of TBV every 3 months (group 2) and 11 dogs donating 15% of 
TBV every 3 months (group 3) for 2 years. 
Variable Group 2 Group 3 
PCV (%) 45.36 ± 3.96 47.55 ± 3.96 
Hb (g/L) 160.64 ± 14.32 164.45 ± 13.81 
RBC count (X 106 cells/μL) 6.65 ± 0.44 6.87 ± 0.64 
MCHC (g/L) 339.27 ± 20.76 334.18 ± 11.39 
MCV (fL) 71.13 ± 3.11 70.68 ± 1.84 
RDW (%) 14.50 ± 2.27  17.73 ± 1.51* 
Platelet count (X 103 platelets/μL) 269.27 ± 67.50 270.00 ± 44.75 
WBC count (X 103 cells/μL) 9.16 ± 2.17 7.82 ± 1.60 
Reticulocytes (%) 1.50 ± 0.73 1.90 ± 1.19 
*Within a row, values differ (*p ≤  0.001) significantly. 
 
Discussion 
In this extended study, there were no significant differences between the initial and 
final iron status biochemical variables in either group, allowing for the conclusion that it is 
safe, for canine donors, to perform blood collections of both 13% and 15% of TBV every 3 
months during 2 years. Similarly, there were no significant differences of the hematologic 
variables when comparing the initial values with those obtained 10 days after the last 
collection. The positive correlation between the RDW, the reticulocyte percentages and 
the number of blood collections not only confirmed this regenerative capacity but 
suggested that it increases over time when animals are submitted to repeated donations. 
This phenomenon seemed to be more accentuated in dogs submitted to the collection of 
15% of TBV, which seems to indicate that, within safe limits, the erythrocyte regenerative 
responses are positively related with the collected volumes. 
 
 
 
 
 
 
 
 
  
 
 
Advances in canine transfusion medicine 
from the health of the donors to transfusion efficacy 
 
  
85 Chapter III – Results 
 
 
 
 
 
 
 
 
2 – Processing and storage of packed red blood cells 
 
2.1 – Laboratory analysis of canine packed red blood cells: effects of 
collection and processing on hemolysis, hemoglobin concentration, 
hematocrit and blood culture. 
 
Ferreira RR, Gopegui RR, Maia S, Matos AJ (2013).  
Comparative Clinical Pathology. Available online. 
DOI 10.1007/s00580-013-1796-3. 
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2.2 – Effects of long-term storage in the hemolysis of canine packed red 
blood cells.  
 
Ferreira RR, Graça RC, Cardoso IM, Gopegui RR, Matos AJ (2014).  
Submited to Veterinary Research Communication. 
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Abstract 
Hemolysis of packed red blood cells (pRBC) is an important indicator of cellular 
integrity, often used as a quality parameter to evaluate deleterious effects induced during 
the blood collection, production and storage of pRBC units. As hemolysis decreases the 
RBCs ability to transport oxygen and may induce transfusion reactions, it is an important 
limiting factor for the shelf-life pRBC. The present study aimed to evaluate the hemolysis 
of canine pRBCs stored in the additive solution SAG-MAN, and to address its associations 
with storage time, duration of the collection process, collection disturbances, and pRBC 
units’ volume and packed cell volume (PCV). Hemolysis of 180 pRBC units was 
determined immediately after processing (t=0). Units were then stored and retested (t=1) 
either before their administration (during weeks 2, 3, 4, 5 or 6 of storage) or at the end of 
the storage period (42 days) if not used. Mean hemolysis at t=0 was 0.09% (SD 0.06) and 
increased during storage, but at a more pronounced rate from the fifth (mean values of 
0.52%, SD 0.29) to the sixth week (1.2%, SD 0.72). Attending to human guidelines that 
recommend a maximum of 1% hemolysis, our results evidenced that all pRBC units with 
36-42 days of shelf-life should be tested for hemolysis before use, as almost 51% of such 
units surpassed this limit. No other blood collection or unit characteristics were related to 
hemolysis of pRBC.  
Key words: pRBC, dog, storage, hemolysis. 
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Introduction   
The use of blood components has become a common procedure in small animal 
medicine. The emergence of several animal blood banks, along with the awareness of the 
advantages of components transfusion is changing the clinicians’ practices toward specific 
component hemotherapies (Chiaramonte 2004; Kisielewicz and Self 2014). As in human 
blood banks, units collected from canine donors can be processed and separated into 
different components, allowing for the extension of erythrocytes shelf life, while 
maintaining the functionality of platelets, clotting factors, globulin and albumin (Blumenthal 
et al. 1999; Wardrop 2008). Component therapy offers many advantages over whole 
blood (WB) administration: it extends components shelf-life up to 6 weeks for packed red 
blood cell (pRBC) units, and 5 years for frozen plasma; allows to treat more than one dog 
per WB unit, maximizing the number of treatments per donation; reduces the risk of 
volume overload by administration of unnecessary components; and reduces the risk of 
transfusion reactions (Chiaramonte 2004; Feldman and Sink 2008a; Helm and Knottenbelt 
2010; Kerl and Hohenhaus 1993; Killingsworth 1984; Stone et al. 1992; Wardrop 2008). 
However, to ensure a permanent availability of blood products, blood banks have to deal 
with higher number of units, stored for longer periods. Thus, a new research area related 
to storage lesions of pRBC is emerging in transfusion medicine.  
Storage lesions are physical and chemical changes that occur in red blood cells 
(RBCs) during storage, which change their structure, decreasing their function and overall 
viability after transfusion (Koch et al. 2008). Adenosine triphosphate (ATP) is 
progressively consumed during storage, especially if the RBCs metabolic activity is not 
reduced by keeping units refrigerated, usually at 4°C (Callan 2010). This ATP reduction 
may lead to protein denaturation and changes in the phospholipid composition of the RBC 
membranes, decreasing their integrity and flexibility, which hampers microcirculation 
(Callan 2010; Prittie 2003; Zimmermann et al. 2003). Moreover, the morphology of RBCs 
progressively changes from biconcave disks to speculate or sphere-shaped cells 
(echinocytes or spherocytes, respectively), decreasing the surface-to-lumen ratio 
(Greenwalt et al. 1991; Pichler and Turnwald 1985; Prittie 2010). Once transfused, these 
RBCs either will be removed by the reticuloendothelial system or will reassume the 
original biconcave shape within 24 hours (Greenwalt et al. 1991). During storage, several 
byproducts, mostly released by leucocytes and platelets, will accumulate in the pRBC 
units. Such components include proinflammatory cytokines (IL-1β, IL-6, IL-8 and tumor 
necrosis factor-α), histamine, complement, lipids, hydrogen ions, potassium, ammonia 
and lactate, and are responsible for the degradation of erythrocytes and transfusion 
reactions, predominantly febrile nonhemolytic (Bracker and Drellich 2005; Prittie 2010). 
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Thus, hemolysis during storage may be related to RBCs factors, such as ATP 
consumption, as well as to bioactive substances generated by leucocytes and platelets. 
In addition to damages during storage, hemolysis may also be caused by 
mechanical injuries during collection or processing of WB units, including shear injuries to 
RBCs caused by clogged needles or tubes, twisted or narrow tubes and small bore 
needles (Patterson et al. 2011; Sowemimo-Cocker 2002). Furthermore, centrifugation and 
RBCs expression into secondary bags thru filters or narrow tubes, may also contribute to 
RBC shear lesions or ruptures (Ferreira et al. 2013; Gkoumassi et al. 2012).   
Hemolysis is a limiting factor for the shelf-life of stored RBCs, not only because it 
significantly decreases the ability to transport and deliver oxygen to hypoxic tissues, but 
also because it may be responsible for transfusion reactions, commonly described as 
nonimmune-mediated hemolysis. These are usually benign and require no treatment, 
although they contribute to a decreased transfusion effectiveness (Harrell and Kristensen 
1995). However, a recent study reported acute life-threatening transfusion reactions in 
four dogs, with three fatalities, upon administration of hemolyzed pRBC units due to 
inappropriate storage (Patterson et al. 2011). Reported clinical signs were similar to an 
acute hemolytic reaction, e.g. hemoglobinemia, hemoglobinuria, fever, prolonged 
coagulation time, thrombocitopenia, petechiae and ecchymosis, melena, hematemesis 
and pulmonary infiltrates responsible for progressive dyspnea (Patterson et al. 2011).   
The concentration of extracellular hemoglobin (Hb) in circulation is controlled by a 
specific plasma binding protein (haptoglobin) and leukocytes (monocytes and 
macrophages) (Buehler and D'Agnillo 2010). When extracellular Hb concentrations 
exceed normal plasma and cellular binding capacities, its plasmatic concentration 
increases, causing important vasoactive and oxidative effects that often lead to acute 
renal failure and vascular dysfunction (Buehler and D'Agnillo 2010).  According to its 
haptoglobin levels, a healthy adult human can be infused with 3 g of free Hb (aproximately 
5 units of pRBCS with 1% hemolysis) without evidence of hemoglobinuria, which usually 
appear when hemoglobin plasma levels reach 1 g/L (Sowemimo-Cocker 2002). Renal 
injuries were described by Harrison et al. (1947) in experimental healthy dogs, after IV 
administration of 20 mL/kg of canine Hb in a 5% solution (Harrison et al. 1947). Renal 
biopsies revealed a tubular urinary flow obstruction due to the accumulation of 
hemoglobin in a gelatinous solution, followed by necrosis of the proximal convoluted 
tubule cells (Harrison et al. 1947). Although an excessive hemoglobinemia (over 3.7 g/dL 
or an average of 2.2 g/dL during 24 hours) is able to cause renal injuries in healthy dogs, 
it is probably an uncommon cause of renal failure by itself, but rather enhances the risk in 
canine patients with concomitant shock, dehydration, renal ischemia or infection (Flink 
1946; Young et al. 1949).  
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Other detrimental effects associated to high free-hemoglobin plasma 
concentrations and non-bound iron content were recently reported, with transfusion of 
older RBCs (42 days of storage time) being related to higher risks of shock and lung 
injury, along with a high mortality rate, in dogs with severe pneumonia (Wang et al. 2014). 
Similar results were obtained in a previous study with massive transfusions of long-time 
stored blood to dogs with induced pneumonia (Solomon et al. 2013). These studies 
indicate that older units should be avoided in dogs with pneumonia and probably in other 
septic patients.    
Due to the reported harmful effects of free hemoglobin, the Council of Europe and 
American Association of Blood Banks (AABB) stipulate that the maximum hemolysis 
percentage of human blood units at the end of storage must not exceed 0.8% and 1%, 
respectively (Europe 2011; Kakaiya et al. 2012). There is currently insufficient information 
for a similar recommendation in dogs, due to scarce information. The shelf-life of packed 
RBCs with citrate base anticoagulants and additive solutions was reported to vary 
between 33 and 42 days, if stored at temperatures of 4±2°C (Abrams-Ogg and Schneider 
2010; Feldman and Sink 2008b; Gibson and Abrams-Ogg 2012; Holowaychuk et al. 2014; 
Kessler et al. 2010; Mathews et al. 2006; Wardrop et al. 1994a; Wardrop et al. 1997).  
The objectives of this study were to evaluate the effect of storage in canine pRBC 
hemolysis, and to determine the potential influence of the collection procedures and pRBC 
characteristics (total volume and packed cell volume – PCV) in the hemolysis of stored 
pRBC. Furthermore, the study aimed to determine if pre-storage hemolysis allows 
predicting the magnitude of the phenomenon at the end of storage.  
 
Material and Methods 
The present study was approved by the ICBAS-UP Ethics Committee (Project 
number 008/2012). A total of 92 WB units were collected from 92 randomly selected 
healthy mixed-breed dogs, weighing 35-60 kg. Dogs had been vaccinated, dewormed and 
had negative PCR (polymerase chain reaction) analysis (Idexx Laboratories, Barcelona, 
Spain) for the following agents: Anaplasma spp., Ehrlichia spp., Babesia canis, 
Leishmania infantum and Dirofilaria immitis. Complete blood counts and chemistry profiles 
were within normal reference ranges. Blood collections were held under the regular 
donation program from a blood bank.  
Whole blood units were collected in commercial triple blood bag (Terumo Medical 
Corporation, New Jersey, USA) without leukocyte depletion filters, consisting of a primary 
bag for the collection of 450±10% mL of blood with 63 mL of CPD anticoagulant (tri-
sodium citrate, sodium phosphate and dextrose), an empty bag for plasma storage and 
one bag with 100 mL of additive solution SAG-MAN (Terumo Medical Corporation, New 
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Jersey, USA), containing adenine, dextrose, mannitol and sodium chloride. After a 
complete physical exam, animals were placed in lateral recumbency, followed by local 
trichotomy and aseptic preparation (using chlorhexidine and alcohol) of the puncture site. 
Jugular venepuncture allowed blood to flow by gravity into the collection bag, which was 
gently inverted to mix the blood with the anticoagulant at every 50 mL of collected volume. 
Approximately 13-15% of the total donor blood volumes were collected and, if an 
interruption of blood flow was noted, the needle was immediately repositioned. Once the 
total volume was obtained, the collection tube was sealed (Composeal, Fresenius Kabi, 
Hesse, Germany). The volumes of blood units were calculated on the basis of their 
weight, assuming that 1 mL of WB weights 1.053 g and that 1 mL of pRBC weights 1.085 
g (Feldman and Sink 2008b). The duration of the collection process, from the 
venipuncture to the removal of the needle, was recorded. The need for needle 
repositioning, animal movements during the procedure, irregular blood flows, or the 
presence of macroscopic blood clots in the collection system were also registered and 
collectively considered disturbances of the collection process. Collected WB units were 
immediately stored using refrigerated butanediol plates (Compocool, Fresenius Kabi, 
Hesse, Germany), keeping a constant temperature of 22±2°C, and processed within 12 
hours. Whole blood unit volumes, including the anticoagulant solution, were registered. 
After a gentle stir, the triple bag system was placed into the centrifuge cups 
(Megafuge 40R, Thermo Scientific, Massachusetts, USA), avoiding plastic folds and 
ensuring a symmetrical distribution of the weight with a tolerated difference of 0.2 g 
between opposite cups. Units were centrifuged at 2000 G for 20 minutes, with 80 seconds 
of acceleration and 110 seconds of deceleration, at 6°C. Plasma was completely 
expressed into the transfer bag, using a manual plasma extractor (Terumo Medical 
Corporation, New Jersey, USA). A volume of 100 mL of SAG-MAN was added to the 
primary pRBC bag. From 88 pRBC units with a final volume above 350 mL, 100±10%  mL 
were expressed into a secondary transfer bag using a sterile connection (CompoDock, 
Fresenius SE, Hesse, Germany), in order to evaluate hemolysis in lower volume units 
(half units). For quality analysis, after gentle mixing by inversion of the pRBC unit, an 8 mL 
aliquot was aseptically separated into a sample bag (Macopharma, Mouvaux, France), 
using a sterile connection (CompoDock, Fresenius Kabi, Hesse, Germany), and 
immediately analyzed (t = 0) for hematocrit, total Hb and plasma supernatant Hb. Packed 
cell volume was obtained using a microhaematocrit centrifuge according to standard 
methodology (Brown 1984). Total Hb was measured using the HemoCue® Hb 201 System 
(HemoCue Inc., California, USA), according to the manufacturer protocol. After 
centrifugation (centrifuge IEC Centra CL3R, Thermo Scientific, Massachusetts, United 
States), plasma supernatant Hb was determined by spectrophotometry using the 
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HemoCue® Plasma Low Hb (HemoCue Inc., California, USA), according to the 
manufacturer protocol. The percentage of haemolysis was obtained using the following 
formula (Sowemimo-Cocker 2002):  
 
% hemolysis = Plasma supernatant Hb (g/L) x (100-PCV) / Total Hb (g/L) 
 
Packed RBCs units were stored at 4°C in a dedicated refrigerator (Fiocchetti, 
Luzzara, Italy) and retested for hemolysis (t=1) either before their administration or at the 
end of the maximum storage period of 42 days, if not used. Bacterial contamination was 
also investigated at t=1 by adding, under sterile conditions, 5 mL of pRBC to aerobic 
culture bottles with specific growth medium (Bact/Alert PF, Biomerieux, Marcy l'Etoile, 
France), followed by incubation at 37°C and continuous examination for 7 days using the 
analyzer Bact/Alert 3D (Biomerieux, Marcy l'Etoile, France). 
For comparison of different storage times, units were grouped according to t=1: 7-
14 days (week 2), 15-21 days (week 3), 22-28 days (week 4), 29-35 days (week 5) and 
36-42 days (week 6) of storage. In order to evaluate the influence of different parameters 
in the hemolysis after different storage times, pRBC units were also grouped according to 
the duration of the blood collection (< 300; 300-360; 361-420; and > 420 seconds), the 
presence or not of collection disturbances, the volumes of initial WB units (< 460; 460-
510; and 511-560 mL) and the volumes (90-100; 200-250; and 251-350 mL) or PCVs (55-
60; 61-65; 66-70%) of the pRBC units.  
Results were analyzed with statistical software (SPSS 22.0.0, IBM, Illinois, USA). 
Normal distribution of data was assessed with the Kolmogorov-Smirnov test. The Pearson 
correlation coefficient was used to assess a possible linear relationship between 
hemolysis, PCV or total Hb and the time of evaluation. Additionally this test allowed to 
evaluate the relation between hemolysis measured before and after the storage time. A 1-
way ANOVA was used to compare differences of the hemolysis according to the following 
variables: PCV of pRBC, volume of the WB unit, volume of pRBC unit and duration of the 
blood collection process. An independent-sample Student t test was used to compare 
differences in hemolysis between normal and abnormal blood collections. Values were 
considered significant at p ≤ 0.05.  
 
Results 
After processing, a total of 180 pRBC units were tested (t=0), of which 88 were low 
volume units (half units). All units were stored and retested once, before its use or 
discharge: 15, 19, 18, 48 and 80 units were analysed respectively during week 2, 3, 4, 5 
and 6 of storage. All pRBC units tested negative for aerobic blood culture. 
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Data for all variables were normally distributed. Hemolysis, PCV and total Hb from 
pRBC units are displayed in Table 1, Figures 1 and 2.  
 
Table1. Mean ±SD values for hemolysis, PCV and Hb determined in pRBC units before and after 
storage. 
  Hemolysis 
 (%) 
PCV  
(%) 
Total Hb 
(g/dL) 
 n M SD M SD M SD 
Before storage 180 0.09 0.06 62.76 3.47 21.37 1.58 
Week 2 15 0.21 0.04 62.27 4.35 21.26 1.72 
Week 3 19 0.36 0.22 62.89 5.27 21.05 1.63 
Week 4 18 0.47 0.18 66.72 4.36 21.01 1.34 
Week 5 48 0.52 0.29 67.71 4.28 21.75 1.37 
Week 6 80 1.20 0.72 69.70 5.25 21.64 1.45 
 
Statistically significant positive correlations between hemolysis (r = 0.73; p < 
0.001); PCV (r = 0.55; p < 0.001) and storage times were found, both values increasing 
during storage time. Hemolysis measured at t=0 ranged from 0.00% to 0.32%. Its 
subsequent increase during storage was not linear, with a steeper increase from the fifth 
(hemolysis ranged from 0.12% to 1.34%; mean 0.52%, SD 0.29) to the sixth week (values 
ranged from 0.23% to 2.47%; mean 1.2%, SD 0.72). By week 5, only 3 units (0.06%) 
presented hemolysis above 1%, the maximum acceptable limit according to the AABB 
(Kakaiya et al. 2012), while by the sixth week of storage 41 units (51%) surpassed this 
recommended value. 
Final pRBC mean hemolysis, measured during week 6, was 1.45% (SD 1.19; n=8) 
in units collected in less than 300 seconds, 1.15% (SD 0.60; n=36) for those collected in 
300-360 seconds, 1.07% (SD 0.72; n=29) in 361-420 seconds and 1.04% (SD 0.47; n=7) 
in more than 420 seconds. Units collected with disturbances evidenced a final mean 
hemolysis of 1.09% (SD 0.52; n=7) while those undisturbed resulted in 1.20% (SD 0.73; 
n=63). Units with less than 460 mL revealed a mean hemolysis of 1.47% (SD 0.95; n=9), 
those with 460-510 mL presented 1.39% (SD 0.66; n=27) and the ones with 511-560 mL 
1.30% (SD 0.72; n=44). Packed red blood cells units with a volume of 90-100 mL 
presented a final mean hemolysis of 1.12% (SD 0.62; n=37), units with 200-250 mL 
evidenced 1.26% (SD 0.76; n=23) and those with 251-350 mL 1.35% (SD 0.65; n=20). 
The final mean hemolysis of pRBC units was, respectively, 0.99% (SD 0.75; n=7), 1.14% 
(SD 0.55; n=14), and 1.09% (SD 0.55; n=59) in pRBC with a PCV of 55-60%, 61-65% and 
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66-70%. There were no significant differences in the hemolysis of the different groups 
within each category.  
In order to analyze the potential to predict hemolysis at the end of storage 
considering the pre-storage hemolysis, Pearson’s correlation test was performed, but as 
no significant differences were found,  both measurements were not correlated (p=0.09). 
 
Figure 1. Hemolysis during storage of pRBC. (p ≤ 0.05) 
 
 
Figure 2. Packed cell volume during storage of pRBC. (p ≤ 0.05) 
 
 
Discussion 
The extent of hemolysis in blood components transfusion is a quality parameter 
and an important indicator of cellular integrity (Sawant et al. 2007). Hemolysis can occur 
by complete RBC rupture or by its ongoing spontaneous degradation, with microvesicles 
containing Hb being formed inside RBCs and released to the plasma (Greenwalt et al. 
1991). The present study intended to evaluate the hemolysis of canine pRBC during 
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storage and to investigate the possible influence of the collection process; pRBC units’ 
volume; and their PCV in this phenomenon.   
 Corroborating previous studies, hemolysis increased over storage time (Brownlee 
et al. 2000; Gkoumassi et al. 2012; Hess et al. 2009; Makroo et al. 2011; Sawant et al. 
2007; Wardrop et al. 1994a; Wardrop et al. 1994b). The cumulative effects of 
proinflammatory substances, mostly released from leucocytes and platelets, along with 
the ATP depletion, that reduces the integrity of RBC membranes, can justify this evidence 
(Bracker and Drellich 2005; Callan 2010; Corsi et al. 2014). Interestingly, a higher 
increase in hemolysis was found during the sixth week of storage. Should the human 
guidelines be applied to dogs, while only 3 units would have to be discarded by week 5, 
such number would increase to 41 units by week 6 (Kakaiya et al. 2012). These data 
highlight the importance of the implementation of a quality control program of stored 
pRBC units, including the evaluation of hemolysis in units with more than 35-42 days, 
despite the reported shelf life of 42 days considered by some authors (Feldman and Sink 
2008b; Holowaychuk et al. 2014; Mathews et al. 2006). In this study, the pre-storage 
hemolysis failed to predict its values after five and six weeks of storage. To the authors’ 
knowledge no previous studies addressed this relation.  
Disturbances of the collection process, the volume of the WB units, the volume of 
stored pRBC units or their PCV, were statistically unremarkable regarding the end-of-
storage hemolysis. A previous human study evaluated more than 10000 pRBC units 
retrospectively and found a direct relation between PCV and the end-of-storage 
hemolysis, concluding, however, that it only explains 1% of the total variability in 
hemolysis (Hess et al. 2009). To the authors’ knowledge, there are no previous 
investigations addressing the other factors evaluated in this study.   
This was the first study evaluating hemolysis in canine pRBC prepared with SAG-
MAN (also known as Optisol® or AS-5) additive solution. Previous similar studies 
evaluated pRBC units with the additive solution Adsol® (Fenwal Laboratories, Illinois, 
USA) and reported an hemolysis of 0.32% ±0.12 in units stored for 35 days (n=6) 
(Brownlee et al. 2000); 0.59% ±0.11 at day 37 (n=4) (Wardrop et al. 1994a) and 0.71% 
±0.57 at day 42 (n=5) (Wardrop et al. 1994b). These values are lower than the ones 
obtained in the present study, which can be explained by the small number of units 
evaluated in the former; by differences in the mannitol concentration of the additive 
solutions; as well as to different methods of determining the supernatant plasma Hb 
concentrations (Hess et al. 2009; Salauze et al. 1984; Zimmermann et al. 2003). 
Furthermore, the study of Brownlee et al. (2000) used prestorage leukoreduction filters, 
which could extend the viability of RBCs as the presence of leukocytes in the pRBC units 
accelerates the hemolysis during storage (Heaton et al. 1994; Sawant et al. 2007).  
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As previously reported, the pRBC units’ PCV increased during storage, which 
could be due to an increase in red cell volume with time, due to degenerative changes 
that permit the ingress of water into the cells (Antwi-Baffour et al. 2014; Walencik and 
Witeska 2007; Zehnder et al. 2008). According to this evidence, Hb concentration seems 
to be a more accurate measurement of the oxygen carrying capacity of pRBC units than 
PCV, because it does not depend on erythrocyte morphology.   
The mere visual inspection of the pRBC supernatant after centrifugation as an 
attempt to evaluate hemolysis has been demonstrated to be inaccurate (Janatpour et al. 
2004). Even when the supernatant is strongly tinged, that does not indicate that the 1% 
level of hemolysis has been surpassed, and the unit can still be effectively transfused 
without clinical sequelae (Sowemimo-Cocker 2002). Thus, besides the potential to identify 
and reject unsuitable units, the hemolysis quantification also prevents the rejection of 
useful units that seem visually improper to be transfused (Janatpour et al. 2004; Sawant 
et al. 2007; Sowemimo-Cocker 2002). 
In conclusion, the results of the present work support the principle that pRBC with 
36-42 days of shelf-life should be tested for hemolysis. Besides storage time, no other 
blood collection or unit characteristics were related to hemolysis of pRBC, and the pre-
storage hemolysis is insufficient to predict its value at the end of the storage period. 
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Transfusion of packed red blood cells in dogs – a preliminary study of 50 
cases 
 
Introduction 
The importance of transfusion medicine in has been growing over the last years in 
companion animals clinic, driven for demands of more specific and effective therapeutic 
choices. After the collection of blood units, several veterinary hospitals and dedicated 
veterinary blood banks are now able to separate WB into different components, mainly 
pRBC and plasma units, but also into more specific products such as platelet 
concentrates, cryoprecipitates and cryosupernatants.1,2 The choice for blood components 
is, therefore, currently considered as the best option as it benefits from the following 
advantages: 1) it extends the components shelf life from 5 weeks (the shelf life of stored 
WB)3 to a maximum of 6 weeks for pRBC and 5 years for frozen plasma4; 2) it maximizes 
the number of treated patients with a single WB donation; 3) it allows for more specific, 
individually tailored, treatments; 4) it reduces the risk of volume overload, particularly in 
dogs with cardiovascular or renal compromises; 5) it reduces the rate of transfusion 
reactions by avoiding exposure to antigens of unrequired components.2,4-10 
In addition to erythrocytes, pRBC units contain a small amount (approximately 
10%) of the original plasma volume.11,12 If leukoreduction is not performed and platelets 
are not separated, these units also possess non-functional leukocytes and platelets.11 
After the separation process, 100 mL of AS are added to each pRBC to provide adequate 
nutrients, allowing for better RBCs storage conditions, which extend their shelf-life and 
facilitates the administration by reducing viscosity.13-15 When administering these units, 
dilution with saline prior to transfusion is not required.14 Packed RBCs units with AS 
should have a final PCV of 55-65 % and a total volume of 200-300 mL.12,14,16-18 
Globally, pRBC units are indicated for clinically symptomatic normovolemic 
anemias resulting from hemolysis, hemorrhage or ineffective erythropoiesis.4,12,17 The 
main purpose of their transfusions is to restore the oxygen-carrying capacity to these 
patients, providing optimal tissue perfusion.17,19 Packed RBCs administration is the best 
available therapeutic option for such purpose, as it not only increases the oxygen carrying 
capacity, but it also improves blood circulation by expanding intravascular volume and 
increasing oncotic pressure.20 Another important advantage of the pRBC administration 
reported in humans is the potential to improve primary hemostasis, as RBCs seem to 
stimulate platelets to produce thromboxane that facilitates platelet aggregation and 
induces vasoconstriction, reducing blood flow to the clot site.21  
The aims of this study were to identify the main causes and clinical signs that led 
to pRBC transfusions, to evaluate the outcome of transfused patients, and to determine 
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the incidence of adverse reactions. Eventually, such data contribute to identify the survival 
prognostic factors for transfused dogs. 
 
Materials and methods 
The present study was approved by the ICBAS-UP Ethics Committee (Project 
number 008/2012). The clinical records of 34 canine patients transfused with pRBCs, 
treated in five veterinary hospitals, were reviewed. Data were registered in dedicated 
blood transfusion sheets. The collected information included: cause of anemia; 
compatibility tests; PCV, storage period and administered volume of pRBC; physical 
exam, arterial blood pressures and PCV before the transfusion, 3 hours and 24 hours 
post-transfusion; signs potentially related to transfusion reactions; duration of transfusion; 
and duration of hospitalization. Packed cell volumes were obtained using a 
microhematocrit centrifuge according to standard methodology.22 Non-invasive systolic 
(SAP) and diastolic (DAP) arterial pressures were evaluated by the oscilometric method 
(Dinamap Carescape V100®, General Electrics Co, New York, USA; or PetMap®, Ramsey 
Inc, Florida, USA) in the metatarsal artery, with dogs in lateral recumbence on a quiet 
non-stressful environment, using cuff widths that were equivalent to 40% of the leg 
diameter. The mean arterial pressures (MAP) were automatically calculated by the 
equipment. The first value was discarded and the seven subsequent measurements were 
registered, if deemed consistent (less than 20% variation). Abnormal readings caused by 
unexpected movements were also discarded. The mean of each pressure was calculated 
from 5 registered measurements, after rejection of the lowest and highest values. Pulse 
rates were measured by digital palpation of the femoral arteries during 60 seconds. 
Mucous membranes color and CRT were evaluated in the labial mucosa.  
Transfusion reactions were considered if receptors developed the following signs 
during transfusion: an increase ≥ 1°C of the rectal temperature, reaching values above 
39°C; vomiting; diarrhea; tachycardia; tachypnea; dyspnea; salivation; angioedema; 
urticaria; hypotension. Red colored plasma and hemoglobinuria in the first 24 hours were 
also considered evidences of intravascular hemolysis due to transfusion reaction.  
Transfusion triggers were not predefined, and in each case both PCV and clinical 
status of the patients influenced the transfusion decision. 
Whole blood units were collected from healthy mixed-breed dogs, weighing 27-60 
kg. The selection of the donors, blood collection procedures, laboratory processing and 
pRBC storage protocols were previously described in this thesis (sub-chapter 2.2). The 
maximum storage time of the pRBC units was 42 days.   
All donors and receptors were blood typed using the migration gel test ID-Gel Test 
Canine DEA 1.1® (Diamed, Lisbon, Portugal) or the imumunochromatographic cartridge 
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method Quick Test DEA 1.1® (Alvedia, Limonest, France), according to the manufacturers’ 
instructions.  In addition, a pre-transfusion crossmatch test was performed in patients 
whose last transfusion took place more than 72 hours before, using the slide method 
described by Mathews (2006).11 Blood transfusions were held with compatible pRBC for 
DEA 1.1 antigen with a negative crossmatching result.  
Normal distribution of data was assessed with the Kolmogorov-Smirnov test. One-
way ANOVA was used to compare pre-transfusion PCVs and its variations after 
transfusion between anemia etiology groups (hemorrhage, hemolysis and ineffective 
erythropoiesis). Specific significant differences between each group were identified by a 
post hoc Tukey test. The same tests allowed to compare differences in the length of 
hospitalization between causes of anemia. To access the correlation between the cause 
of anemia and the number of transfusions or the mortality, a chi-square test was 
performed. Independent samples Student’s t-test was used to evaluate differences 
between survivors and patients who died before discharge, in the following parameters: 
pRBC volume, duration of transfusion, length of hospitalization, pre-transfusion PCV and 
PCV variation after 3 and 24 hours. The differences between the results of pre-transfusion 
and post-transfusion physical exams were evaluated either by the chi-square test (for 
mentation and mucosa color) or by one-way ANOVA and the post hoc Tukey test (for 
pulse rate, respiratory rate, temperature, SAP, MAP and DAP). The critical probability for 
statistical significance was taken to be p ≤ 0.05. Previous tests were performed using 
SPSS statistical software. 
 
 Results 
A total of 50 pRBC transfusions to 34 patients were analyzed. Six dogs received 2 
blood transfusions, 2 dogs received 4 transfusions and 1 dog was transfused 5 times. 
Eighteen studied patients were females (53%) and 16 males (47%); ages ranged between 
2 and 15 years; weight varied from 1.4 to 39 kg; several pure breeds were included 
although the larger group was constituted by mongrels (29.4%); 14 dogs (41.2%) were 
DEA 1.1 negative and 20 (58.8%) DEA 1.1 positive. Twenty two dogs (64%) were 
transfused due to hemorrhagic anemia, 6 (18%) to hemolytic anemia and 6 (18%) to 
ineffective erythropoiesis.  
Data collected during transfusions is summarized in Tables 1 and 2, and Figure 1. 
Evaluation of PCVs from patients grouped according to the cause of anemia (hemolysis, 
hemorrhage or ineffective erythropoiesis), revealed a significant higher pre-transfusion 
PCV in patients with hemorrhage (Table 3). The cause of anemia was not significantly 
related with the number of transfusions, length of hospitalization, or mortality.  
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Packed RBCs volumes and shelf life, duration of transfusion, length of 
hospitalization, pre-transfusion PCV or post-transfusion PCV variations, were compared 
with the animals´ outcome (death or survival) but no significant differences were 
demonstrated.  
Pre- and post-transfusion clinical signs are displayed in Table 4. Three and 24 
hours after transfusion, dogs evidenced significantly lower pulse rates; furthermore, after 
transfusion the number of alert patients and dogs with pink mucous membranes increased 
significantly.  
Three non-hemolytic febrile transfusion reactions were identified (6% of total 
transfusions), all in first-time transfused animals. The survival rate was 71%, with 10 dogs 
dying before hospital discharge, 3 of them through euthanasia.  
 
Table 1. General data from 50 transfusions to 34 dogs. 
 pRBC 
volume 
(mL) 
pRBC  
PCV  
(%) 
pRBC 
shelf life  
(days) 
Duration of 
transfusion 
(minutes) 
Hospitalization 
(days) 
Mean 217.9 59.6 13.6 149.1 4.8 
SD 109.6 5.0 12.4 39.7 3.7 
Min 20 51 0 60 0.5 
Max 522 70 40 210 12 
n 43 47 47 21 32 
 
Table 2. Pre- and post-transfusion PCVs (%).  
 Pre-
transfusion 
 
Post-
transfusion 
3 hours  
Post-
transfusion 
24 hours  
Variation 
pre-3h 
Variation 
pre-24h 
Variation 
3h-24h 
Mean 15.5 23.9 21.3 6.6 6.5 -0.7 
SD 5.7 8.3 5.6 6.0 5.7 6.1 
Min 5 8 5 0 -3 -16 
Max 32 43 34 16 23 8 
n 50 26 27 26 27 22 
 
Table 3. Packed cell volume (%) variations according to the different causes of anemia. 
  Hemolysis 
 
Hemorrhage 
 
Ineffective 
erythropoiesis 
 
 n Mean SD Mean SD Mean SD p 
Pre-transfusion 50 12.46 6.38 17.32 5.04 13.00 4.00 ≤ 0.05 
Variation (pre-3h) 26 3.68 9.33 7.72 4.64 6.00 5.29 > 0.05 
Variation (pre-24h) 27 6.50 8.10 5.48 4.71 8.20 2.49 > 0.05 
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Figure 1. Comparison of pre- and post-transfusion PCVs (%) according to the different causes of 
anemia. 
 
 
Table 4. Pre- and post-transfusion clinical signs. 
 
Pre-transfusion Post-transfusion 
3 hours 
Post-transfusion 
24 hours p 
 
Pulse rate (p.p.m.)  
Mean 143.0 123.8 117.7 ≤ 0.01 
SD 25.0 28.4 28.3  
Min 104.0 70.0 72.0  
Max 188.0 171.0 172.0  
n 30 22 15  
 
Respiratory rate (r.p.m.)  
Mean 38.7 32.4 38.7 ns 
SD 17.2 12.7 23.3  
Min 16.0 16.0 12.0  
Max 88.0 60.0 92.0  
n 30 29 18  
 
Temperature (°C)  
Mean 37.9 38.4 38.1 ns 
SD 0.9 0.8 0.7  
Min 35.6 36.7 36.7  
Max 40.3 40.2 39.2  
n 32 22 16  
 
SAP (mmHg)  
Mean 135.1 142.4 142.2 ns 
SD 18.9 24.5 20.8  
Min 86.0 81.0 102.0  
Max 174.0 182.0 190.0  
n 29 22 14  
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Table 4. cont’d. 
 
MAP (mmHg)  
Mean 92,9 102,9 97.1 ns 
SD 17,2 20,1 17.9  
Min 55,0 67,0 66.0  
Max 125.0 153.0 140.0  
n 29 22 14  
 
DAP (mmHg)  
Mean 71.1 80.1 73.7 ns 
SD 17.0 20.0 15.0  
Min 39.0 48.0 53.0  
Max 101.0 132.0 115.0  
n 29 22 14  
 
Mucous membrane color - Pale/Pink  
 
91%/9% 50%/50% 47%/53% ≤ 0.01 
n 33 22 17  
 
Mentation - Lethargic/Alert  
 
84%/16% 81%/19% 61%/39% ≤ 0.05 
n 31 21 18  
 
Discussion 
The risks and benefits of pRBC transfusion, which must always be evaluated 
before deciding for its use, must be based not only on the patients’ needs but also on the 
factors that favor or harm the individual outcome, both patient-related and transfusion unit-
related. Hence, studies evaluating pre- and post-transfusion clinical and analytic 
parameters are of paramount importance and may provide invaluable information on such 
a decision. One of the weaknesses of this preliminary study is the fact that data were 
recorded by practitioners from different veterinary hospitals, rendering incomplete 
information on some transfusion sheets. Another important limitation was the evaluation of 
some qualitative clinical signs, such as mentation and mucous membrane color that could 
have been evaluated in a non-uniform way by different clinicians.      
The majority of the reported pRBC transfusion studies were focused on acute 
hemorrhagic patients which was similar to our study.6,23,24 Bleeding, however, may be due 
to several conditions - trauma, neoplasia, coagulopathies or surgical losses. Furthermore, 
the acute presentation of the majority of these cases makes them more prone to rapid 
decompensation, regardless of their PCV values, increasing their need for blood 
transfusions. This may also justify the significantly higher pre-transfusion PCVs of 
hemorrhagic patients, when comparing to those with hemolysis or ineffective 
erythropoiesis.  
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Three hours after the transfusion the overall mean increase in PCV was 6.6%, 
which was similar to results published by Silvestrini et al. (2011) but smaller than reported 
by Kisielewicz et al. (2014).23,25 In the latter, a mean pRBC volume of 14.8 mL/kg (7.1-41.7 
mL/kg) was transfused, which is significantly higher than the mean transfused volume in 
our study (9.8 mL/kg). The clinical advantages of such a conservative approach cannot be 
compared because survival rates were not reported in that study. Although the 3 hours 
post-transfusion PCV increases were similar among patients with different causes of 
anemia, the 24 hours evaluation demonstrated that such variation continued in patients 
with ineffective erythropoiesis, whereas it decreased in hemorrhagic and hemolytic 
patients. It is possible that ongoing hemorrhage or hemolysis perpetuate the RBCs loss, 
including transfused cells, hindering the complete long-term effectiveness of pRBC 
transfusion. To the authors’ knowledge, this is the first study comparing the immediate 
and longer term effectiveness of pRBC transfusions. In a previous study, the mean PCV, 
measured 12 hours after transfusion, increased similarly in all dogs, regardless of the 
causes for anemia.23 
In previous reports, initial PCV alone was not considered a good predictive factor 
for transfusion need, since the clinical status of the patients was also of the utmost 
importance in such a decision.6,9,26 Some authors postulated that blood transfusions 
should be reserved for animals presenting tachycardia, bounding or week femoral pulse, 
pale mucous membranes, tachypnea, hypotension, cardiac arrhythmias, weakness, 
fatigue, hypothermia or collapse.4,9,17 In our study, abnormal pre-transfusion values of 
pulse rate, respiratory rate, temperature, and SAP/DAP were detected in 33%, 43%, 56% 
and 31%, respectively. Besides, 91% of the receptors evidenced pale mucous 
membranes and 84% were lethargic. At least 2 clinical signs were presented by 94% of 
the patients (mean 3.2 signs, range 1-7), with only two dogs presenting exclusively pale 
mucous membranes.  
Corroborating previous studies, all clinical variables improved within 3 hours after 
transfusion, although only pulse rate, mucous membrane color and mentation were 
significantly different from the pre-transfusion results. It is possible that the small size of 
our sample, along with a very probable variability of clinical evaluation procedures 
performed by different practitioners, hampered the statistical recognition of existent 
differences.  
In this study, we were unable to identify significant differences between dogs that 
survived and those that died before discharge. A recent study reported higher mortality 
rates in animals with higher pretransfusion PCVs and those receiving higher volumes of 
pRBC, an evidence that seems to favor a more conservative transfusion strategy in 
dogs.27 As in our study, previous reports failed to find significantly different mortality rates 
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amongst dogs suffering from anemia due to different causes, although patients with 
hemangiossarcoma tended to have worse survival rates.23,24,28,29 
The occurrence of transfusion reactions (6%) was lower than in the majority of 
previously published similar studies (from 3% to 40%).6,24,27,29-31 This low frequency may 
be explained by several factors. The absence of hemolytic reactions is probably the result 
of a strict administration of compatible pRBC, after blood typing and crossmatching; the 
conservative lower volumes of the administered pRBC units were probably responsible for 
the inexistence of transfusion-associated circulatory overloads; the careful selection of 
blood donors, proper processing practices and storage conditions reduced the likelihood 
of nonimmune-mediated hemolysis, sepsis or dilutional coagulopathy. It is possible that 
such low prevalence of transfusional reactions could be further reduced if leukoreduction 
filters were used, since it has been demonstrated that leukodepleted pRBC units are less 
probable to induce nonhemolytic febrile reactions.23 Delayed reactions, described in 
previous reports, could not be documented in this study due to the short period of post-
transfusion follow-up. The determined survival rate of 71% was similar to the highest 
frequencies previously reported, ranging between 29% and 73%.6,23,24,27-29 Certainly, the 
low number of transfusion reactions and good processing, storage, and compatibility tests 
practices contribute to a higher therapeutic success. However, a stricter triage of critical 
patients could have reduced the fatalities by decreasing the number of animals whose 
clinical condition was so poor that they would no longer benefit from the procedure.   
These preliminary results, although limited, allow us to confirm the effectiveness of 
pRBCs transfusions as their benefits clearly outweigh the risks of transfusion reactions. 
Although no risk factors for survival were determined, this study will continue in the hope 
of gathering enough information to allow for their identification, as well as the 
characterization of factors influencing the effectiveness of pRBC transfusion.  
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Every day the life of several patients in critical conditions depends on the 
transfusion of blood products. As industrial blood substitutes are not widely available yet, 
their administration remains as the only option to treat anemic patients. However, blood is 
a life tissue to be intravenously administered, so detailed safe collection, processing and 
storage protocols must be elaborated and strictly followed. The health and welfare of 
canine blood donors should also be a major concern in a blood donor program, not only 
due to obvious ethical reasons but also because calm, confident and healthy donors will 
certainly turn the collection processes easier, faster and with less waste of consumables. 
Thus, it is important to develop canine transfusion medicine, by changing old habits, 
based on the administration of unscreened and untyped WB, towards the creation of 
blood banks where the health of donors and the safety of components are ensured.  
This thesis aimed to draw attention on the improvement of blood transfusion 
practices, to add scientific data that substantiate the elaboration of protocols for collection, 
processing and storage of pRBC, and to propose new areas of investigation.    
 The blood volume that can be safely collected from canine donors is not 
consensual in published reports, ranging from 11% to 25% of TBV.4,5,9,10,12,25,33,38,48-50 To 
the author’s knowledge, only one clinical study of canine blood donors properly addressed 
the hemodynamic effects of the procedure, but it was developed in Greyhounds that have 
important physiologic peculiarities comparing with other breeds.51 All other publications 
about the subject were based on the author’s experience rather than on specifically 
designed clinical studies. In addition, no previous studies evaluated sedated donors. Our 
study evaluated the influence of blood depletion in the hemodynamic variables (non-
invasive arterial blood pressures and pulse rates) in sedated and non-sedated donors. 
While non-sedated dogs did not evidence potentially harmful variations in pulse rates or 
arterial blood pressures, in donors that had to be sedated possible deleterious 
hemodynamic effects were registered when higher blood volumes were collected. Thus, 
collections of up to 15% of TBV in non-sedated dogs and 13% of TBV in sedated dogs 
were considered safe procedures in dogs. Although it would be interesting to evaluate 
higher collection volumes, further field research must never include procedures that 
constitute risk to the health of the studied donors. Besides, donations of 15% of TBV by 
dogs weighting more than 33 kg allow to collect a standard unit of 450 mL WB, avoiding 
the need for the collection of higher volumes.  
 The cumulative effects of repeated donations must also be considered when 
frequent donors are enrolled. No previous studies addressed such effects, although 
several authors recommend that donations can be safe when preformed every 1 to 8 
weeks.4,5,9,10,12,33,38,48-50 Our study was designed to evaluate the bone marrow regenerative 
response and iron status of canine frequent donors, submitted to 2 years of repeated 
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blood collections. Significant elevations of post-collection RDW, PLT, WBC and 
reticulocyte percentages were evidenced in all groups, meaning that the bone marrow 
regenerative response was able to restore the depleted blood cells within 10 days of blood 
collection. However, 1 year after the donation of 13% of TBV every 2 months, dogs 
evidenced a significant decrease of serum ferritin, suggesting a decrease of their iron 
stores. Thus, donors submitted to this protocol should be routinely monitored for their iron 
status. The remaining protocols did not induce significant differences in iron status, 
meaning that the regular iron alimentary intake is able to compensate for such depletions. 
Another relevant finding was the positive correlation between the number of collections 
and both RDW values and reticulocyte percentages found in all groups, which suggests 
that the bone marrow regenerative responses to the erythrocyte depletion improved along 
the time in frequent donors. Further studies extending the duration of the donation 
program will shed light in this theme and allow for the definition of the limits for the 
duration of dogs as blood donors. However, our results preclude the study of more 
frequent donation programs, due to their potential deleterious effects. 
 The laboratory processing of WB and the effects of storage in pRBC units were 
also addressed in this thesis by the evaluation of the relationship between collection and 
processing techniques and the quality of the pRBC units, based on the evaluation of the 
final pRBC volume, Hct, Hb concentration, hemolysis and bacterial contamination. The 
results obtained were within the reference range of the human blood bank guidelines, 
meaning that proper collection and processing protocols were used, ensuring the quality 
of pRBCs. Suitable techniques were also confirmed by blood cultures, as a single 
contaminated pRBC unit (0.4%) was identified. No significant differences in hemolysis 
were detected when factors related to sedation, blood collection, time to processing or 
centrifugation protocols were studied. However, as hemolysis was significantly higher 
when post-centrifugation analyses took 48-72 hours to be performed, this quality control 
should be performed in shorter periods.  
Since storage of blood components is essential to ensure permanent and easy 
access of stocks, it is very important to address its effects on the quality of pRBC units. 
Hemolysis, an indicator of cellular integrity, is often used in human blood banks as a 
quality parameter to evaluate the blood collection, units’ production, and storage 
deleterious effects. Although some previous studies evaluated the hemolysis of small 
number of stored canine pRBC units,28,30,65,223 the SAG-MAN (AS-5) had not been tested 
before. The present study aimed to evaluate the hemolysis of canine pRBCs in this AS, 
and to address its associations with storage time, duration of the collection process, 
collection disturbances, and the volume and PCV of pRBC units. Our results evidenced 
that only storage time was related to hemolysis of pRBC. Moreover, hemolysis evidenced 
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a linear increase until the fifth week and a more pronounced rate between the fifth and the 
sixth weeks, when almost half of the units presented more than 1% hemolysis, the 
maximum recommended value of human guidelines.192 Thus, our results suggest that all 
pRBC units with 36-42 days of shelf-life should be tested for hemolysis, as it decreases 
the RBCs ability to transport oxygen and may induce transfusion reactions.189 Despite the 
evidence of low hemolysis in aged pRBC units until the fifth week, further prospective 
studies are needed to address the effects of such old units in the morbidity and mortality 
rates of canine patients. 
Blood compatibility was also investigated in this thesis, as it is often overlooked, 
although it increases the risks of pRBC transfusions. This study intended to evaluate the 
risks of untyped blood transfusions by identifying the prevalence of the erythrocyte antigen 
DEA 1.1 in Portugal. The evidenced high frequency of DEA 1.1 (56.9%) allowed to 
estimate a high risk (24.5%) of sensitization following a first transfusion with non-typed 
and non-crossmatched blood, and a small but important probability (6%) of acute 
hemolytic reactions after a second transfusion in sensitized patients. Thus, it is highly 
recommended to blood type both donors and patients before any pRBC transfusion, 
decreasing the risk of acute and delayed immune-mediated hemolytic reactions. 
Additionally, our study allowed to determine breed-related frequencies, helping to predict 
DEA 1.1-positivity when blood typing methods are not available. 
The clinical benefits and potential risks should always be estimated before pRBC 
transfusions. Our study aimed to identify the main causes and clinical signs that led to 
pRBC transfusions, to evaluate the outcome of transfused patients and to determine the 
incidence of adverse reactions. Additionally, data were analyzed to identify survival 
prognostic factors for transfused dogs. Although 3 hours after the transfusion the overall 
mean PCV increase was 6.6%, different variations were registered between 3 and 24 
hours after transfusion according to the cause of anemia. Furthermore, all clinical 
variables improved within 3 hours after transfusion, although only pulse rates, mucous 
membrane colors and mentation were significantly different from the pre-transfusion 
results. The benefits of pRBC transfusion confirmed previous data.46,55,140,141,144,147 
Transfused patients presented a survival rate of 71%, with no significant differences 
related to volumes and shelf life of pRBC, duration of transfusion, length of hospitalization 
and patients’ PCVs, compromising the identification of risk factors. These preliminary 
results allowed to confirm the effectiveness of pRBCs transfusions but additional data is 
needed to properly assess the risk factors for survival. Published retrospective studies 
evaluated pRBC transfusions without predefined transfusion triggers.46,55,141,147 It would be 
very interesting to prospectively investigate the use of a conservative vs liberal transfusion 
strategy in dogs, by evaluating the utility of a critical PCV and/or a clinically-based 
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“transfusion-need” scale as transfusion triggers, in the prediction of survival rates and 
length of hospitalizations. Another important issue is the evaluation of the benefit of pRBC 
administration in the primary hemostasis of bleeding dogs, considering the human 
evidences of transfusion-related increased platelet aggregation and secondary 
vasoconstriction.168   
In transfusion medicine, the patients’ safety should be optimized by several 
procedures: adequate donor selection and care; suitable blood collection technique, 
laboratory components processing and quality control programs; and careful transfusion 
and patients monitorization plans. As in human transfusion medicine, strictly regulated by 
governments and health care organizations, clear guidelines, able to help in the 
standardization of procedures and development of quality control programs, will certainly 
be part of the small animal transfusion medicine. This thesis aimed to add relevant 
information for such advances, thus helping to improve the safety of transfusion related 
procedures for both canine donors and patients. 
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